Effects of acute and sub-chronic glucocorticoid treatments on hippocampal neurons of wild type and dystrophin-deficient DMDmdx mice: an in vitro and in vivo study by Cosmi, Francesca
	 1	
  
 
 
SAPIENZA 
Università di Roma 
Facoltà di Scienze Matematiche Fisiche e Naturali 
 
DOTTORATO DI RICERCA IN BIOLOGIA CELLULARE E 
DELLO SVILUPPO 
 
 
30° Ciclo 
(A.A. 2016/2017) 
 
 
Effects of acute and sub-chronic glucocorticoid treatments on 
hippocampal neurons of wild type and dystrophin-deficient 
DMDmdx mice: an in vitro and in vivo study 
 
 
 
 
Dottorando: 
Francesca Cosmi 
 
 
Docente guida  
Prof.ssa Maria Egle De Stefano 
Coordinatore  
Prof.ssa Giulia De Lorenzo 
 
 
  
	 2	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 3	
 
 
 
 
 
 
 
 
 
 
 
 
 
“I do not know what I may appear to the world, but to myself I 
seem to have been only like a boy playing on the seashore, and 
diverting myself in now and then finding a smoother pebble or 
a prettier shell than ordinary, whilst the great ocean of truth lay 
all undiscovered before me.” 
Sir Isaac Newton 
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Abstract 
 
Duchenne muscular dystrophy (DMD) is a lethal X-linked 
disease characterized by progressive muscular wasting due to 
lack of full-length dystrophin (Dp427), a cytoskeletal protein 
expressed in muscle and selected brain regions (i.e. 
hippocampus). Dp427 binds to a large multi-proteic complex 
(Dystrophin Glycoprotein Complex, DGC), endowed with 
structural and functional properties, as the modulation of 
several intracellular signaling pathways. The presence of the 
dystrophin-DGC in areas involved in cognitive functions 
suggests that lack of Dp427 may be responsible for the 
neurological disturbances described in DMD patients. These 
could be further aggravated by the glucocorticoid (GC) 
therapeutic treatments of the muscular inflammation in DMD 
patients. As the hippocampus is one major GC target, in this 
study I analyzed whether in vitro (acute) and in vivo (acute and 
sub-chronic) treatments with either corticosterone (CORT) or 
dexamethasone (DEX) affected the already compromised 
hippocampal neuron physiology. Under any conditions we 
analyzed several parameters of the neuronal response to GCs: 
a) protein levels of the glucocorticoid receptor (GR) and of its 
phosphorylated (active) form pGR; b) mRNA levels of GR and 
GILZ; c) changes in the intensity of GR and pGR 
immunohistochemistry; d) protein levels of GR intracellular 
signaling effectors (i.e. caveolin 1, ERK 1/2); e) proliferation 
of hippocampal neural progenitor cells (NPC) (in vivo sub-
chronic treatment only). In both in vitro and in vivo studies, 
mdx mouse hippocampal neurons respond differently than wild 
type to GC treatments. The general picture emerging is that 
they could be more sensitive to GCs and, therefore, more 
predisposed to be damaged. In fact, even acute GC 
administrations elicit a response similar to the more damaging 
	 12	
chronic administration: i.e. reduction in GR levels, increase in 
the ration pGR/GR, possible reduction in GR gene expression, 
all aspects that are connotative of a chronic stress response. 
During high level of stress, which correspond to high and 
prolonged levels of secreted GCs, several physiological 
responses are altered, including those typical of hippocampal 
activity: i.e. synaptic plasticity, cognitive functions. These are 
accompanied by a reversal of the GC effects on hippocampal 
neurons: from the promotion of neuronal activity, and hence of 
its inhibitory control over the HPA axis, to its reduction, with 
consequent depression of HPA axis activity and increase in GC 
secretion. These are the basis for psychopathologies, as post-
traumatic disorders. Therefore, the already compromised 
activity of the hippocampus in dystrophic subjects could be 
further damaged even by mild doses of GC, amplifying the 
risks for serious neural hilliness. Another crushing data is that 
sub-chronic treatments with DEX induce an increase in the 
proliferation of NPC in adult hippocampus, in contrast to what 
occurs in the wild type. This de-regulation of precursor cell 
cycle, responsible for of glia and neuronal self-renewal in adult 
brains, could further compromised hippocampal physiology. 
In conclusion, in the hope that new therapies could extend the 
life span of the young DMD patients, it is important to go 
deeper in the comprehension of how hippocampus and other 
brain areas affected by DMD, respond to anti-inflammatory 
(GCs) treatments. 
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Introduction 
 
1. The Duchenne Muscular Dystrophy and the dystrophin 
protein 
The Duchenne Muscular Dystrophy (DMD) is the most 
common form of muscular dystrophy and the second most 
common genetically inherited disease, affecting approximately 
1 in 3500 live male births (1). The disease is characterized by a 
progressive and devastating muscular degeneration, which 
primarily affects skeletal muscles, and subsequently cardiac 
and respiration muscles, causing premature death of DMD 
patients within their 20s (2). The disease is caused by the lack 
of a large cytoskeletal protein of 427 KDa called dystrophin 
(Dp427) (3). 
The dystrophin gene, localized on the short arm of the X 
chromosome, is one of the largest human genes so far 
described, comprising almost 0.1% of the genome, (4) and 
consisting of 79 exons (5) encoding a primary transcript of 
2400 kilo-bases. Due to its large size, this gene has a high 
mutation probability, so that nearly one third of DMD cases are 
non-familial (6). The dystrophin gene is quite complex, hosting 
at least eight independent and tissue-specific promoters. The 
full-length dystrophin isoform (Dp427), for instance, is 
transcribed by three independently regulated promoters, 
labelled as B (brain), M (striated muscle), or P (Purkinje cell), 
the respective letters reflecting the major sites of expression 
(7). Apart from the Dp427, five additional isoforms exist, 
produced by activation of different promoters along the gene or 
by alternative mRNA splicing. These shorter isoforms are 
named according to their molecular weights: Dp260 
(predominantly in the retina), Dp140 (central nervous system 
and kidneys), Dp116 (peripheral nervous system), Dp71 (most 
tissues, but not muscles), and Dp40 (brain) (8, 9, 10 ). 
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Fig 1: Schematic diagram showing the position of all promoters within the 
dystrophin gene and the molecular structure of the dystrophin isoforms. 
Tissue distribution of dystrophin and its isoforms are also indicated (11) 
 
Muscle dystrophin is localized at the cytoplasmic face of 
the sarcolemma membrane and consists of an N-terminal actin-
binding domain, a central large rod-like domain composed of 
spectrin-like repeats, and a cysteine rich C-terminus (Fig. 1) 
that connects to a multiproteic complex called the dystrophin-
associated glycoprotein complex (DGC) (Fig. 2).  
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Fig 2: The dystrophin-associated glicoprotein complex in skeletal muscles 
(12)  
Central protein of the DGC is dystroglycan (DG), 
composed by the transmembrane b-DG and the extracellular a-
DG, sarcoglycans (a, b, g and d), sarcospan, syntrophins (a1, 
b1, b2, g1, g2), and dystrobrevin (13). In this complex, while 
the b-DG binds to dystrophin, which in turn links to the cortical 
actin filaments, the a-DG binds to extracellular matrix (ECM) 
proteins, as laminin. Therefore, the DGC provides a link 
between cytoskeleton and ECM (14), which is thought to 
protect the muscle plasma membrane (sarcolemma) from 
mechanical damages. Sarcoglycan is the second 
transmembrane component of the DGC, connected to b-DG 
and dystrobrevin. On the cytoplasmic side, instead, dystrophin 
directly interacts with syntrophins and dystrobrevin, which 
recruit other scaffolding proteins onto which signalling proteins 
(i.e. nitric oxide synthase) and ion channels are anchored to the 
plasma membrane (15). In this way, the DGC provides both a 
physical and functional connection between the internal and 
external environment of muscle cells.  
In DMD, the absence of Dp427 results in the 
destabilization of the DGC, which not only hinders muscle 
integrity, but also induce secondary changes reflecting an 
impairment in intracellular signalling, as could be the reduction 
in nitric oxide synthesis and, hence, protein nitrosylation (16). 
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2. Dystrophin expression and localization in the nervous 
system 
Selected neuronal populations (within hippocampus, cortex, 
cerebellum, autonomic ganglia) and glial cells (i.e. 
oligodendrocytes, Schwann cells) of both central and peripheral 
nervous systems also express Dp427, some of its isoforms and 
proteins composing the DGC (17). In brain, the Dp427 is 
primarily located in the hippocampus, prefrontal cortex, 
amygdala and cerebellum (18, 19). Here, similarly to skeletal 
muscles, it associates to the DGC, although several brain DGC 
variants exist because of the various dystrophin isoforms, 
alternatively spliced variants, and the presence of other DGC 
components, such as b-dystrobrevin, e-sarcoglycan, and the g-
syntrophins (Fig. 3), which are not expressed in muscle. 
Moreover, the Dp427-DGC localizes not only in domains along 
the plasma membrane, but also at post-synaptic specializations, 
in which the complex does not bind to laminin but to the pre-
synaptic protein neurexin (Fig. 3) (15). 
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Fig 3: Neuronal DGC localized within post-synaptic specializations. When 
Dp427-DGC are localized in the post-synaptic domains, dystrophin binds to 
β-dystrobrevin and the dimer β-DG/a-DG, which in turn associates with the 
pre-synaptic protein neurexin-α. This contributes to synaptic stabilization. 
In addition, part of the DGC is also α1- and γ1-syntrophins, absent in 
muscles. These proteins, by binding Dp427 and dystrobrevin, are involved 
in the stabilization of ion channels within the membranes, among which 
voltage-gated Na+ channels. In addition, syntrophin also bind and stabilize 
at the DGC the neuronal nitric oxide synthase. The all complex is also 
implicated in the stabilization of post-synaptic receptors, as GABAA 
receptors. (Abbreviations: DGC dystrophin-associated glycoprotein 
complex; nNOS neuronal nitric oxide synthase; SAST syntrophin- 
associated serine/threonine kinase; ABD actin-binding domain; EFI/EFII EF 
hand domains; ZZ zinc finger domain; H1/H2 helical domains) (15)	
 
Due to these differences, the DGC in the nervous system is 
often referred to as a DGC-like (15, 20). This complex 
associates not only with the Dp427, but also with all its shorter 
informs. Localization of full-length and short dystrophin 
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isoforms is cell-specific: for example, Dp427 is mainly 
neuronal, although has also been described in 
oligodendrocytes; Dp260 and Dp140 are highly represented in 
the retina, especially in neurons of the inner nuclear layers 
(21); Dp140 has also been found in perivascular astrocytes, 
along the Dp71, the most ubiquitous dystrophin isoform (22, 
16, 8, 23); Dp116 is mainly expressed by Schwann cells of 
peripheral nerves. 
 Full-length dystrophin is mainly localized in specific 
neuronal populations, as hippocampal neurons (all regions), 
cortical pyramidal cells, and cerebellar Purkinje cells (24). 
Major localization in adult individuals (both human and animal 
models) is at the postsynaptic sites, which has suggested a role 
in the maintenance of synaptic structure and function (16). The 
Dp427 has been found to co-localize with the g-aminobutyric 
acid type A (GABAA) receptors possibly through their linkage 
to syntrophins and gephyrin. This would prevent receptor 
diffusion (25), playing a critical role in their clustering, 
stabilization and synaptic signal transmission (26, 27, 1, 28, 29, 
30).  
In both autopsy brains of DMD patients and mdx mice 
(elective animal model of DMD), absence of Dp427 does not 
induce gross anatomical alterations, but a number of diversified 
cellular and sub-cellular abnormalities, among which: 50% 
decrease in cortical neuron number and neural shrinkage (31), 
abnormal dendritic development (32), altered post-synaptic 
density organization and pre-synaptic ultrastructure in 
hippocampus, mainly in the CA1 region (33, 34, 35, 17). In 
addition, in mdx mice, loss of Dp427 has been associated with 
a reduction in 40–70% of GABAA receptor clusters in CA1 and 
CA3 hippocampal neurons (containing the alpha-2 subunit), 
cerebellar Purkinje cells (containing the alpha-1 subunit), 
amygdala and cerebral cortex (containing both alpha-1 and 
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alpha-2 subunits) ( 36, 26, 37). GABAA alpha-1 and/or alpha-2 
receptor subunit gene expression was also decreased in these 
brain regions. In brain, dystrophin deficiency has also been 
associated to a reduction in the response to nicotine in a passive 
avoidance memory task (engaging hippocampal activity) (38). 
This suggested a role of Dp427 in the stabilization of nicotinic 
acetylcholine receptor (nAChR) subtypes, similarly to GABAA 
and glutamatergic receptors. Whether all these alterations are 
the morpho-functional basis of cognitive dysfunctions has been 
a matter of discussion for long time, others failed to 
demonstrate this correlation (39, 17). 
 Because brain dystrophin is more abundant in the 
hippocampus compared to other sub-cortical areas (19), 
selective behavioural deficits involving hippocampal function 
were predicted to occur in the mdx. Indeed, several studies 
showed that dystrophin deficiency in mdx mice is associated 
with impaired memory retention at long delays, in certain 
procedural learning and spatial alternation tasks (40, 41), 
suggesting a role for Dp427 in the consolidation of certain 
forms of long-term memories. Absence of Dp427 also causes 
unbalanced calcium homeostasis (42), with consequent 
alterations in hippocampal long-term potentiation (LTP) (43), a 
form of plasticity widely believed to be critical for memory 
formation. Intriguingly, dystrophin deficiency in CA1 
hippocampal neurons appeared to facilitate induction of short-
term potentiation (STP) and depression (STD) of the 
glutamatergic transmission (41, 29), with no apparent alteration 
in the maintenance of the LTP phase (41). Recently, brain 
dystrophin was found in association with a sub-population of 
GABAA receptors at inhibitory synapses (36, 44) and the 
abnormal enhancement of hippocampal STP and STD was 
shown to be occluded by a GABAA-receptor antagonist (29), 
suggesting that decreased inhibitory tone may be one possible 
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mechanism of the altered plasticity in dystrophin-deficient 
neurons. At the functional level, this induces alterations in 
other mechanisms of plasticity, such as the LTP of the 
population spike (PS), with important consequences on the 
output of the neuronal circuitry. 
Duchenne De Boulogne was the first describing 
cognitive limitations in boys with DMD (45). General 
intelligence among boys with DMD is one standard deviation 
below the normal population mean IQ and mental retardation 
has been reported in approximately one third (34.8%) of 
patients (46). Moreover, boys with DMD can be affected by 
attention-deficit/hyperactivity disorders (ADHD) (1.7 %), 
autism spectrum disorders (3.1 %) and reading problems (20 % 
moderate, 20 % severe) (47). Mutations in the dystrophin gene 
can even cause intellectual disability in the absence of 
muscular dystrophy (48). However, since these cognitive 
deficits do not seem to depend on the location of the gene 
mutations, a clear genotype-phenotype correlation for cognitive 
impairment in DMD has yet been established (17, 20). As the 
gene encodes several dystrophin isoforms, the number of 
affected gene products and/or cell-type specific isoforms may 
correlate with the occurrence and severity of cognitive 
impairment (49, 20).  
DMD also associates to peripheral nervous system 
(PNS) alterations. Autonomic dysfunctions have been reported 
in DMD patients (50), and a number of morphological and 
functional alterations have been reported by studies conducted 
in our laboratory on the sympathetic neurons of the superior 
cervical ganglion (SCG) of mdx mice. Specifically, loss of 
Dp427 induces an early (since post-natal day 0, P0) and 
persistent reduction in the SCG noradrenergic innervation of 
iris and heart, compared to wild type mice, which associates 
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with a significant loss in muscle-innervating ganglionic 
neurons between P5 and P10 (51). Moreover, all mdx mouse 
ganglionic neurons, regardless of the type of target they 
innervate, showed reduced defasciculation and terminal 
branching (51). De-regulated protein levels for components of 
the nerve growth factor (NGF) signalling system (i.e., NGF 
receptors TrkA and p75 NTR) (52), unbalanced 
proNGF/mature NGF ratio (52), and reduction in the NGF-
mediated intracellular signalling cascade were also described 
(53). Moreover, a reduction in intra-ganglionic a3, b2/ b4 
nAChR stabilization (54) and activity (55), as well a different 
modulation in the expression of genes encoding proteins 
involved in neuron survival and differentiation (56) were also 
reported.  
3. Therapeutic approaches for DMD treatment  
Although DMD was discovered more than twenty years ago, 
there is currently no cure to resolve the disease. In fact, the 
most widespread pharmacological therapy focuses on the use of 
a glucocorticoid-based treatment, aimed to reducing muscle 
inflammation and the activity of the immune system, to 
alleviate the dystrophic phenotype and increase motor activity 
in DMD affected patients (57). The action of these drugs can 
improve muscle strength, ambulation and cardiac activity. 
However, this therapy is associated with multiple side effects, 
such as weight gain, CNS disorders, gastrointestinal and 
metabolic disorders (58). To date, new therapies based on 
genetic techniques, able to restore the products of the dmd 
gene, are being tested. In fact, by acting on the dystrophin pre-
mRNA, it can induce the exclusion of exon containing the 
mutation and generate a truncated and partially functional 
protein. However, the presence of a semi-functional dystrophin 
improves the patient's motor skills, reducing the severity of 
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symptoms and lengthening life expectancy, but there were no 
significant improvements in cognitive function following 
treatment with drugs, mainly because the administration is 
intramuscular and the drug has a local action (59). 
One of the main objectives in this area is to find a non-invasive 
treatment, effective both on the muscular and the nervous 
phenotype. 
 
4. The glucocorticoid-mediated stress signalling 
4.1 Glucocorticoids and their receptors 
Glucocorticoids (GC) are steroid hormones and the end product 
of following the activation of the hypothalamus-pituitary-
adrenal (HPA) axis, which regulates stress responses. GC, like 
all steroid hormones, are synthesized from cholesterol, which 
undergoes multiple transformations in a multi-enzymatic 
process called steroidogenesis. GCs are neurosteroids, a large 
group of steroid hormones, which includes allopregnanolone 
and allotetrahydrodeoxycorticosterone (THDOC), testosterone-
derived androgens (androstanediol) and estradiol. 
Neurosteroidogenesis occurs in the brain regions such as 
cortex, hippocampus, and amygdala. The type of steroid 
hormone synthesized in a particular endocrine gland is 
determined by the combination of the enzymes it expresses. 
The main enzymes for the synthesis of glucocorticoids are: 17-
hydroxylase, 3β-hydroxysteroid dehydrogenase, 21-
hydroxylase and 11β-hydroxylase (60). 
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Two types of receptors 
mediate the GC effects: the 
mineralcorticoid receptor 
(MR) and the glucocorticoid 
receptor (GR), both 
expressed in several brain 
regions. Among these areas 
there is the hippocampus, in 
which the great abundance of 
GC receptors makes it an 
important relay for both 
stress appraisal and 
adaptative processes. Through MR, GCs influence the brain’s 
appraisal of novel information and memory retrieval, and 
thereby influence behavioural coping responses. As GC 
concentrations increase in response to stressors, GR are 
activated to promote stress adaptation, reallocation of energy 
resources in preparation for future events and recovery of the 
system (61). One important target of GCs is the BDNF-
signalling, which crucially contributes to the modulation of 
axonal guidance, synaptic plasticity and neurite outgrowth (62). 
MR, GR and the BDNF receptor, TrkB, are co-expressed in 
hippocampal neurons, supporting this region as the primary site 
of immediate interactions between the GC- and BDNF-
signalling pathways (63). Ultradian fluctuations of GCs (Fig. 4) 
drive GR activation and reactivation, whereas MR occupancy 
is more constant and promotes excitability (64). This balance 
has implications for the genomic and non-genomic activity of 
adrenal steroids within target cells. 
The GR belongs to the nuclear receptor superfamily, which 
includes receptors for steroid hormones (e.g. glucocorticoids, 
estrogens, androgens and mineralocorticoids) as well as 
receptors for other hydrophobic molecules, such as 
Fig. 4: Schematic ultradian 
fluctuation of GCs in healthy 
individuals 
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prostaglandins, fatty acids and thyroid hormones. Nuclear 
receptors share a similar structural organization and mode of 
action, via transcriptional activation (transactivation) or 
repression of transcription (trans-repression). The GR consists 
of three main domains; the N-terminal domain (NTD), the 
DNA-binding domain (DBD) and the ligand-binding domain 
(LBD), with a hinge region between the LBD and DBD. This 
modular structure is broadly conserved across the nuclear 
receptor superfamily. The DBD is the most conserved region 
across the nuclear hormone receptor superfamily. It contains 
two “zinc finger” structural motifs, the N-terminal zinc finger 
binds specifically to the DNA response element (glucocorticoid 
response element, GRE), and the second is thought to be 
involved in protein-protein interactions, such as when the 
receptor forms a dimer. Once a dimer of GR binds GRE, it can 
recruit co-regulators and chromatin-remodelling complexes 
that modulate gene transcription rates by affecting the activity 
of RNA polymerase II (65). The LBD is localized at the C-
terminal end of the protein. The structure of the binding pocket 
consists of 12 α-helices and four β-sheets that form a 
hydrophobic pocket to which the steroid hormone 
preferentially binds. This conformational structure is dependent 
on the co-association of the chaperone protein hsp90, which 
maintains the receptor in the open position in order to accept 
ligand binding (66). Once a GC binds the LBD, a 
conformational change leads to the dissociation of chaperones 
and exposure of the nuclear localization signals. Post-
translational modifications of the NTD occur via 
phosphorylation and sumoylation. Human GR phosphorylation 
occurs at serine residues 203 and 211 in response to hormone 
binding, and is thought to influence receptor localization within 
the cell, with phosphorylation of Ser203 causing the receptor to 
be cytoplasmic, and phosphorylation of Ser211 promoting 
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translocation into the nucleus (67). GR phosphorylation 
changes its interaction with cofactors and influence target gene 
expression (68).  
 
4.2 The glucocorticoid receptor genomic response 
Steroid hormones have a typical arrangement of four 
cycloalkane rings, and are derived from enzymatic processing 
of cholesterol. Their lipophilic nature allows them to enter the 
cell by diffusion through the plasma membrane, in order to 
bind the cytoplasmic GR, which is held in the open 
conformation by heterocomplex of chaperones, such as 
immunophilins and heat shock proteins (hsp). As said, this 
binding induces a receptor conformational change, dissociation 
of chaperone proteins, receptor phosphorylation and exposure 
of nuclear localization signals (NLS). This signal is recognized 
by importins, which are proteins for the import into the 
nucleus, and translocated into this compartment (69). Here, 
GRs dimerize and bind, via the zinc finger motifs to the GRE, 
which are conserved signals upstream to target genes. This 
binding can either enhance or repress gene transcription, 
depending on the GRE present and the availability of other 
transcription factors. If GRE is a promoter of transcription, 
bound GRs recruit co-activators and other transcription factors, 
leading to increased chromatin remodelling, recruitment of 
further co-factor, and eventual recruitment of RNA polymerase 
2 (RNA Pol II). In case of a “negative” GRE (nGRE), GR 
binding causes repression of target gene transcription, possibly 
by blocking the promoter site, or other transcription factor 
binding sites. Rogatsky and collaborators (70) identified some 
genes directly regulated by GC binding to GRE. These include 
glucocorticoid-induced leucine zipper (GILZ), IGFBP1, and 
metallothionein 1X (MT1X). In particular, GILZ is involved in 
cell proliferation, epithelial sodium channel activity (71), and 
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plays key roles in GC signal-modulation, control of protein 
trafficking and signalling, modulation of T-lymphocyte and of 
other immune cell activation, IL-2 production and apoptosis 
(72, 73). GILZ interacts, inhibiting, with NF-kB, AP-1, Raf-1 
and Ras, which are negative regulators of GC signalling, as 
they normally inhibit GC target gene expression, as trans-
repression of pro-inflammatory genes (i.e., cytokines and their 
receptors, nitric oxide synthase, COX-2). Treatments with 
dexamethasone (DEX), a potent GR synthetic agonist, up-
regulate GILZ expression, which mimics some of the GC 
effects, adding further immunosuppressive effects (74). 
 
4.3 The glucocorticoid receptor non-genomic signalling 
GC genomic response is necessarily a rather long process. 
Gene transcription and expression, along with post-
translational processing of proteins, may take several hours, 
with the minimum time for an effect to be measurable of at 
least 15 minutes. However, GC also elicit a number of fast 
responses (within a few seconds to minutes), which are not 
sensitive to inhibition of both transcription and protein 
synthesis, and that can be observed also in cells that don’t have 
a nucleus, such as platelets. These non-genomic signalling can 
be investigated by using GR inhibitors, such as RU-486, which 
inhibit the classical ligand-binding activation of cytosolic GR, 
or by stimulation with DEX conjugated to BSA (DEX:BSA). 
BSA complexing gives rise to a compound unable to cross the 
plasma membrane and approach intracellular receptors, hence 
triggering a signalling cascade, which must be via a membrane-
associated receptor (75, 76, 77) (Fig. 5).  
Several mechanisms have been proposed for the non-genomic 
effects of GC signalling. These include effects mediated by a 
membrane-associated GR (mGR), via GC ligand-binding to a 
different receptor to the GR, such as glutamate receptors, or 
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acting via G-protein coupled receptors, or having a direct effect 
on the membrane (75, 78). Effects of GC signalling to the 
cytosolic GR have also been proposed to elicit non-genomic 
effects via proteins released when the receptor complex is 
disrupted upon ligand binding. The effects observed have 
included activation of second-messenger systems, changes in 
ion flow, and activation of kinase pathways (79). Xiao and 
collaborators (80) demonstrated that GC rapidly and non-
genomically activate ERK1/2, JNK, and p38 mitogen-activated 
protein kinases (MAPK) in GR-deficient neurons, but had no 
detectable effects on their neuronal viability. CORT rapidly 
activates both the cAMP-PKA pathways and the ERK1/2 
pathway in neurons, important in the hippocampal response to 
stress (81, 82). Evidence for the involvement of the PI3K 
pathway has not yet been studied in the brain.  
Over the last decade, highly ordered plasma membrane 
micro-domains with particular lipid and protein composition 
have been identified. There is evidence that these domains, 
termed “lipid rafts,” orchestrate some control over intracellular 
signalling pathways and mediate cross talk between membrane-
associated receptors (83). Current evidence suggests that the 
estrogen receptor is associated with a particular sub-set of lipid 
rafts termed “caveolae” (84). Caveolin-1, the major protein 
component of caveolae, has been implicated as a structural 
scaffold for the oligomerization and organization of 
cytoplasmic signal complexes (85). Interaction with, and 
modulation by, caveolin-1 has been shown in many signal 
transduction pathways, including those regulated by mGR. 
Caveolae can act as signalling organizers, and several works 
established a role for Cav1 in a rapid GC signalling pathway 
that triggers MAPK activation in embryonic mouse neural 
progenitor cells (NPC) cultures. In this case, one of the 
consequences of Cav1-dependent activation of MAPK by GCs 
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is an inhibition of intercellular communication between NPSCs 
coupled by gap junction (86). Studies with other steroid 
hormone receptors (i.e., androgen and estrogen receptor) have 
revealed mechanisms of cross talk between the genomic and 
the rapid GR responses (87).  
MAPKs are a superfamily of serine-threonine kinases 
composed by the well-characterized extracellular signal-
regulated kinases (ERK1 and ERK2 MAPK isoforms of 44- 
and 42-kDa, respectively), the c-Jun-NH2-terminal protein 
kinase/stress-activated protein kinase (JNK/SAPK) and the p38 
MAPK (88). They are activated by diverse stimuli ranging 
from cytokines, growth factors, neurotransmitters, hormones, 
as well as under conditions of cellular stress and cell 
adherence. They play a key role in the regulation of cell 
growth, differentiation, cytoskeletal function, and gene 
expression (89, 90). As demonstrated in PC12 cells, GCs might 
act via its membrane receptor and activate ERK1/2 MAPK. 
ERK1/2 MAPK sustained activation results in its nuclear 
translocation (91, 92), which is then capable of regulating gene 
transcription itself (93, 94). 
Current evidence suggests the estrogen receptor interact 
with caveolin-1 (84, 95). In addition, association of the GR 
with membrane lipid rafts has also been proposed (96), as 
confirmed by immunoprecipitation studies showing co-
precipitation of GR and caveolin-1 (97). Moreover, as a 
control, loss of caveolin expression prevents GC inhibition of 
cell proliferation, an effect mediated by blocking the cells in 
G1/S transition (97). Recent data support integration of 
different signalling cascades to determine integrated cell 
responses (98).  
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Fig 5:	GR signalling pathways. Glucocorticoid-activated GR regulates gene 
expression by three main routes: (A) binding directly to DNA, (B) tethering 
itself to other DNA-bound transcription factors, (C) binding directly to 
DNA and interacting with neighbouring DNA-bound transcription factors. 
GR can also signal using a non-genomic pathway, by using membrane-
bound GR and activating various intracellular signalling kinases. (77) 
 
5. The stress response  
Stress represents a condition that implies a modification of 
homeostasis, which may occur through a number of different 
events regulating emotion, behaviour, cognition as well as 
physical health. Indeed, stress represents the main 
environmental components for the susceptibility to mental 
illness, although it is known that the response to stress is 
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modulated by the genetic signature, as well as by a number of 
other factors, including earlier exposure to adverse life events 
that may have ‘primed’ the brain toward enhanced 
susceptibility. The majority of studies have reported that 
exposures to stress or elevated levels of corticosteroids impair 
performance on memory tasks dependent on the hippocampus 
(99, 100). Memory impairments have also been reported in 
transgenic mice with elevated corticosterone (CORT) 
production, due to central overexpression of corticotrophin-
releasing factor (CRF). Recent findings of stress altering the 
firing properties of place cells in the hippocampus (101), which 
are thought to support spatial navigation and memory, are 
consistent with the stress effects on spatial memory tasks. The 
discovery of a relationship between stress and hippocampal 
LTP is significant, because it offers both a testable synaptic 
mechanism that may explain stress effects on memory and a 
“neurophysiological marker” to compare behavioural results 
from studies that use different stress paradigms. For example, a 
chronic restraint stress causes reduction in hippocampal 
volume from the pre-stress size (102), which determines 
reduction in the number of dendritic spines and branches of 
pyramidal neurons in the CA3 (103) and suppression of the 
production of new granule neurons in the dentate gyrus (DG) 
(104). The abundant presence of the GR in rodent and human 
hippocampus makes this brain structure, together with the 
hypothalamic paraventricular nucleus (PVN), very sensitive to 
the action of GCs and key to the regulation of the stress 
response (61, 105).  
GRs are central in the regulation of stress response and 
other situation where GC levels are elevated (106, 61, 107), 
since basal levels of CORT will not occupy all the receptors, 
leaving some vacant for signalling the response to stress. 
Prolonged exposures to CORT have also been shown to cause 
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morphological and molecular changes, reduced neurogenesis 
and impaired synaptic plasticity in the hippocampus, 
physiological outcomes which are thought to precipitate 
hippocampus-dependent memory impairments and anxiety- and 
depression-like behaviours (108) (Fig. 6). These long-term 
effects of chronic CORT elevation on the hippocampus have 
been hypothesized to occur via epigenetic mechanisms (i.e., 
DNA methylation and histone modification) in the HPA axis 
(109). 
 
 
Fig. 6: Biological effects of stress on the hippocampus. As the severity 
(intensity, duration) of stress increases, alterations in neurochemicals, 
synaptic plasticity, neural activity, cytoarchitecture, and neurogenesis occur 
in the hippocampus that can influence subsequent cognitive functions, such 
as learning and memory, and contribute to psychopathologies. + and – 
represent an increase and decrease in hippocampal functioning, respectively. 
(110) 
In response to stressful or threatening situations, 
corticosteroids are released by the HPA axis (Fig 7). Neuronal 
signalling to the PVN of the hypothalamus in response to 
proposed that when an organism internalizes that its action
has no bearing on the aversive outcome (stressor), this learn-
ing produces changes in the cognitive, emotional, and motiva-
tional systems that impede subsequent learning. The learned
helplessness phenomenon, where stress-associated learning nega-
tively influences subsequent learning, in essence, is the negative
counterpart to the concept of meta-learning in humans, which
Maudsley (1979) described as “the process by which learners be-
come aware of and increasingly in control of habits of perception,
inquiry, learning, and growth that they have internalized.” In re-
cent decades, much research has shown that stressful experiences
can alter hippocampal mnemonic functioning in animals and
humans.
The vast majority of studies have reported that exposures to
stress or elevated levels of CORT impair performance on memory
tasks dependent on the hippocampus (McEwen and Sapolsky
1995; Kim and Diamond 2002). In human studies, individuals di-
agnosed with PTSD and depression are impaired in various verbal
recall tests (Bremner et al. 2000). The evidence for the direct role of
CORT is based on findings of memory deficits in patients with
Cushing’s syndrome (with chronic hypercortisolemia; Starkman
et al. 1992), and in healthy subjects administered with CORT
(Newcomer et al. 1994). Similarly, rodent studies have shown
that exposures to stress and injections of high doses of CORT pro-
duce deficits in spatial memory tasks that involve the hippocam-
pus (de Quervain et al. 1998). Memory impairments have also
been reported in transgenic mice with elevated CORT due to cen-
tral overexpression of corticotropin-releasing factor (CRF;
Heinrichs et al. 1996). Recent findings of stress altering the firing
properties of place cells in the hippocampus (e.g., Kim et al. 2007),
which are thought to support spatial navigation and memory
(O’Keefe and Dostrovsky 1971), are consistent with the stress ef-
fects on spatial memory tasks.
However, stress does not produce globalmemory deficits as it
has been shown to enhance cerebellum-dependent eyeblink con-
ditioning (Beylin and Shors 2003) and amygdala- and hippocam-
pus-dependent contextual fear conditioning, which is thought to
be due to prior stress augmenting glucocorticoid release during
training (Cordero et al. 2003). Interestingly, the same stress that
impairs hippocampal memory tasks seems to enhance the
relative use of competing nonhippocampal (e.g., the caudate-
dependent stimulus-response) memory tasks in rats and humans
(Kim et al. 2001; Schwabe and Wolf 2012). At present, it is un-
known whether these differing effects on memory are indirect,
i.e., the result of stress decreasing the hippocampus’ ability to in-
teract (e.g., compete) with other brain–memory systems, or direct
facilitatory effects on nonhippocampal memory systems.
Stress and hippocampal plasticity
Long-term potentiation (LTP), resulting from a brief high-
frequency stimulation of afferent fibers initially demonstrated in
the hippocampus, has characteristics desirable of a synaptic mod-
el of memory, such as rapid induction, longevity, stimulation
threshold requirement (cooperativity), strengthening by repeti-
tion, input specificity, and associativity (see Bliss andCollingridge
1993). The first evidence linking LTP and stress was reported by
Thompson, Levine and colleagues who found impairments in
the Schaffer collateral/commissural-CA1 LTP in hippocampal slic-
es prepared from rats that experienced 30 intermittent tailshocks
during 30 min of restraint (Foy et al. 1987). Importantly, CA1 LTP
was relatively normal in hippocampal slices from rats that re-
ceived the same amount of tailshocks but were able to terminate
them voluntarily (Shors et al. 1989), indicating that, similar to
learnedhelplessness, the LTP impairment is largely due to the psy-
chological, rather than physical, qualities of stress.
Stress-associated LTP impairments have also been demon-
strated in the dentate gyrus (e.g., Shors and Dryver 1994) and
CA3 regions of the hippocampus (e.g., Pavlides et al. 2002).
Other studies have found time-dependent, biphasic effects of
stress on LTP—an initial enhancing effect followed by a longer-
lasting, suppressing effect on LTP (Akirav and Richter-Levin
1999). Stress has also been reported to enhance LTP induced by
u-burst stimulation but impair LTP induced by high-frequency
stimulation. These findings indicate that differences in stress par-
adigms, in vitro versus in vivo recordings, and stimulation pat-
terns produce a more complex picture of stress effects on LTP.
The discoveryof a relationship between stress andhippocam-
pal LTP is significant because it offers both a testable synaptic
mechanism that may explain stress effects on memory and a
Figure 1. Biological effects of stress on the hippocampus. As the
severity (intensity, duration) f stress increases, alterations in neuroch m-
icals, sy aptic pl sticity, neural activity, cytoarchitecture, and neuro-
genesis o cur in the hippocampus that an influence sub equent
cognitiv functions, such as learni g and m mory, and con ribute to
psychop thologies. + and 2 represent an increase and decrease in hip-
pocampal functioning, respectively. Adapted from Kim a d Yoon (1998).
Figure 2. The hypothalamic-pituitary-adrenal (HPA) axis. A major neu-
roendocrine system associated with various bodily and behavioral
activities. None of these compounds or structures responds uniquely to
stress. (PVN) paraventricular nucleus of hypothalamus, (CRF) corticotro-
pin-releasing factor, (AVP) arginine-vasopressin, (ACTH) adrenocortico-
tropic hormone, (GCs) glucocorticoids, (CAs) catecholamines, (Enk)
enkephalins.
Neurobiology of stress
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perceived danger causes the release of corticotrophin releasing 
hormone (CRH) and vasopressin, which stimulates the release 
of adrenocorticotrophic hormone (ACTH) from the pituitary 
gland into the blood stream. This is carried to the adrenal 
glands, above the kidneys, where it stimulates production of 
corticosteroids, such as mineralocorticoids and GC, from 
cholesterol by the adrenal cortex (61).  
HPA axis activity is organized in a circadian rhythm with 
high levels in the morning, enabling individuals to cope with 
energy demands ahead of them. It is important to note that 
rapid HPA axis activation by acute stress and the subsequent 
turn-off of the HPA axis by the negative feedback response of 
CORT is healthy, as it helps an individual to cope with the 
stressor (111) (Fig. 7). 
 
 
 
 
Fig 7: Under normal conditions, the presence of a stressor stimulates the 
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paraventricular nucleus of the hypothalamus to release CRH and 
vasopressin, which induce the release of ACTH from the anterior pituitary 
gland. ACTH stimulates the synthesis and release of glucocorticoids from 
the adrenal cortex. As a result of the deleterious effects of long-term 
exposure to glucocorticoids, a strict glucocorticoid-feedback mechanism, 
acting at the pituitary, hypothalamic and hippocampal levels, is fundamental 
to modulate the activity of the HPA axis. Particularly, the activation of 
hippocampal glucocorticoid-receptor-expressing neurons exerts a potent 
inhibition of the HPA axis. Modified from Vitale et al., 2013 
 
In order to respond quickly to dangerous stimuli, the 
body must produce an adaptive behavioural response such as 
increased locomotion and risk assessment. A physiological 
response is also produced by the sympathetic action of the 
autonomic nervous system to produce the so-called “fight or 
flight” response via acetylcholine (Ach), epinephrine and 
norepinephrine signalling.  
Corticosteroid signalling in the brain modulates the stress 
response, with mineralocorticoids affecting appraisal of the 
situation, and GC acting on consolidation of information (112). 
The hippocampal formation is a powerful upstream modulator 
of the HPA axis stress response and consequent emotional 
states (114). Imbalances in circulating levels of GCs can lead to 
defects in hippocampal functioning, and vice versa (106). The 
production of GC has an inhibitory effect on the HPA axis, 
inhibiting the release of CRH and ACTH, to decrease the 
release of further corticosteroids, this occurs in a delayed 
genomic manner, but effects have been found to occur within 
5-15 minutes. The neurons of the PVN of the hypothalamus 
have a high number of GRs, which would account for the 
genomic inhibitory effect on the HPA axis. The production of 
ACTH at the pituitary is also inhibited in a fast, as well as 
delayed manner, and although the mechanism is still unclear 
(113), GR-dependent and GR-independent signalling may be 
involved (114).  
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6. Glucocorticoid effects on adult hippocampal neurogenesis  
The hippocampal formation is a powerful upstream modulator 
of the HPA axis stress response and consequent emotional 
states (115). Imbalances in circulating levels of GCs and stress 
context can lead to defects in hippocampal functioning and vice 
versa (106); among these is adult neurogenesis, which occurs at 
the DG level (116, 117). On the other hand, correct 
hippocampal neurogenesis is important in the hormonal 
regulation of stress response, as it gives rise to a small subset of 
neurons that are critical for a powerful negative control of the 
hippocampus over the HPA axis.	 Defects in hippocampus 
structure and function may be manifested by HPA-axis 
deregulation (118), which is associated with many forms of 
affective disorders (119). Conversely, enhancing neurogenesis 
can improve mood-related behaviour and restore central control 
over stress response systems (120).  
The hippocampus is divided into three main sub- 
regions, named CA1, CA3, and DG. Neuronal cells derived 
from these three sub-regions are connected by the so-called tri-
synaptic pathways. It is generally assumed, but not proven, that 
information processing by this pathway is crucially involved in 
learning and memory formation. Neurogenesis occurs only in 
the DG and there is no evidence that other hippocampal regions 
generate new neurons (121). Adult hippocampal neurogenesis 
refers to neural stem/progenitor cells (NSPCs) present in the 
sub-granular zone (SGZ) of the hippocampal DG, where they 
continue to produce new neurons during adulthood in many 
species, including human (122, 123). New neurons have been 
implicated in various hippocampus-related functions and 
disorders, such as spatial learning and memory, pattern 
separation, epilepsy, anxiety, depression and dementia (124, 
125, 126, 127, 128). Recent reports further indicate that new 
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neurons also play an important role in HPA axis feedback 
regulation after stress: mice lacking new hippocampal neurons 
have a slower recovery of CORT levels to baseline after stress. 
Other studies also indicated that hippocampal new born 
neurons play an important role in stress regulation, as increased 
adult hippocampal neurogenesis exerts antidepressant effects, 
improves behaviour and regulation of stress response (118, 
120, 129, 130, 131).  
Both acute and chronic stress can suppress one or more 
phases of adult hippocampal neurogenesis (132, 133, 117). For 
example, predator stress rapidly raises GC levels, which cause 
significant reductions in hippocampal NSPC proliferation, 
(134, 135). While many, if not all, of these effects are generally 
attributed to increased GC levels, a simple interpretation of the 
effects of corticosteroids on the regulation of adult 
hippocampal neurogenesis is difficult to provide and it is 
important to realize that many other variables can influence 
both hippocampal neurogenesis and the way GCs regulate it 
(136, 117). Therefore, the reactions of the endocrine system to 
stress, and the results of that activation on neuronal function, 
are modulated by other events and may vary in complex ways. 
The sum of this pattern determines how a given stressor alters 
adult hippocampal neurogenesis in a given individual at any 
one time. Multiple stages of the neurogenic process are 
affected, including proliferation, as subsequent neuronal 
differentiation, connections to output pathways (e.g. CA3) and 
dendritic growth. Stress not only reduces NSPC proliferation 
and adult hippocampal neurogenesis, it may also control 
subsequent NSPC fate specification and differentiation through 
the action of the GR, which has important consequences for 
hippocampal network connectivity, function and behaviour 
(137). Direct effects of GCs on NSPCs have been demonstrated 
in the absence of known stressors, showing that the GR plays a 
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central role in mediating the direct effect of CORT on 
hippocampal NSPCs, as selective reduction in GR expression 
in new born cells results in altered neurogenesis (137). Clearly, 
the effects of stress and stress hormones on adult neurogenesis 
are complex. Firstly, neuronal stem cells in the SGZ of the DG 
are located in a specialized microenvironment, the so-called 
neurogenic niche, consisting of numerous different cell types, 
including astrocytes, ependymal cells, blood vessels, 
interneurons, oligodendrocytes, and myeloid cells, i.e., 
microglia cells and dendritic cells. All this cell types may 
modulate adult neurogenesis. For example, depending on the 
type of microglia and on the challenge, activated microglia 
cells release cytokines that may have detrimental or beneficial 
effects on adult neurogenesis (138). Also, these cell types 
express GRs indicating that stress-induced GC elevation targets 
these cells, which may modulate the rate of neurogenesis. 
Secondly, the nature of the stressor is an important factor.  
NSPC express both GR and cell-specific mechanisms 
regulating its activity at the level of intracellular trafficking, 
suggesting an important biological function for the GR in these 
cells (139, 140). Consistent with a role in NSPC differentiation, 
knocking down GR expression in the new born cells results in 
increased NSPC differentiation (137), demonstrating that direct 
effects of CORT on these cells via the GR exist as well.  
An important question that emerges is what type of 
environmental factors regulating adult neurogenesis also affect 
GR levels in neuronal progenitor cells. Interestingly, early life 
events, such as maternal separation and parental care, are 
known to reduce GR levels at adult age by epigenetic 
programming of the GR promoter (141, 142, 143, 144) and 
associate with impaired adult neurogenesis (145, 146). Aging is 
associated with lower rates of hippocampal neurogenesis (147), 
impaired negative feedback of CORT on the HPA axis, and 
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reduced levels of the GR (148, 149). Chronic stress is another 
factor negatively affecting both GR levels and adult 
neurogenesis attenuating multiple excitatory and inhibitory 
signalling cascades through the GR (150, 151, 152).  
GCs inhibit cell differentiation and synaptic development in the 
various brain regions, resulting in alterations in neural fine 
structure and functions (153, 154, 155). Prenatal stress 
diminishes neurogenesis in the DG of juvenile rhesus monkeys 
(156) and, throughout postnatal life, GCs exert suppressive 
effects on cell proliferation in the DG. Moreover, persistently 
high CORT levels decrease cell proliferation in the adult rat 
DG (157). DEX has been shown to produce cell loss in the 
pyramidal layers and DG (158) and elicit various effects on 
neural cells. It has also been reported to cause an arrest of HT-
22 cells (mouse hippocampal neuronal cell line) in the G1 
phase of the cell cycle (159) and inhibit platelet-derived growth 
factor-induced differentiation of HiB5 cells (hippocampal stem 
cell line) (160). The sensitivity of DG to glucocorticoids is of 
particular concern because DG is also an important brain center 
involved in the synaptic plasticity. The two aspects of 
neurogenesis, which includes proliferation and differentiation, 
could be independently affected by GC activation (161). 
 
7. Glucocorticoids and DMD 
CNS alterations associated to DMD are reported in patients and 
animal models. However, differently from muscles, nervous 
system defects are mainly established prenatally and difficult to 
identify, as functional alterations become apparent during 
growth. Different anatomical alterations induce diversified 
neurological disorders with different degree of severity. Among 
these, children and adolescent with DMD are at great risk of 
developing depression and anxiety disorders (162).  
To date, there is no proximity to cure for DMD 
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neurological aspects, but new pharmacological treatments are 
succeeding in extending patients life span. Despite different 
innovative therapeutic approaches are in the stage of clinical 
trial, the treatment based on corticosteroid administration, 
which reduces skeletal muscle recurrent inflammation, 
continues to be the main adopted therapy (163). In healthy 
individuals, increase in GC synthesis and release follows the 
coordinated activation of the HPA and autonomic system. The 
ubiquitous expression of GR and the multitude of functions of 
GCs confer this system an essential role in the response to 
stress and restoration of homeostasis. Precise regulation of the 
HPA axis activity is very important for the organism; indeed, 
chronic exposure to GCs end up in various adverse side effects, 
such as osteoporosis, diabetes, hypertension, neurodegeneration 
(164) and inhibition of neurogenesis (111, 165, 161). On the 
other hand, a deficient HPA axis is observed in a wide range of 
autoimmune and inflammatory disease. GCs reach every organ 
by way of the circulation and cross the blood brain barrier, 
which allows the coordination of brain and body functions. 
Several experimental evidences underline the relevance of 
corticosteroids as structural modulators in the limbic areas. 
Both acute (single) and chronic (repeated) stress stimuli induce 
prominent changes in neuronal activity and synaptic functions, 
in hippocampus and medial prefrontal cortex, which rely on 
neuronal remodelling (i.e. dendrite shortening and pruning) 
(166). A great number of genes are also inhibited directly by 
GCs, through the formation of a repressor complex containing 
histone deacetylases (HDACs). Alteration, at any level, in GC 
mode of action is observed also in aging and in 
neurodegenerative diseases (167).  
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Aim and Scope 
Goal of this research project is to explore the effects that 
increased levels of GCs exert in brain regions particularly 
susceptible to stressful stimuli, such as hippocampus, in DMD. 
The animal model used has been the mdx mouse, a genetic 
model of the disease in which a spontaneous point mutation in 
the exon 23 induces an anticipated stop codon in the dystrophin 
gene, resulting in absence of full-length dystrophin synthesis. 
Numerous experimental evidences are shedding a light on the 
role that Dp427 plays in different brain regions. Among these 
are hippocampus and cerebellum, which are field of 
demonstrated brain physiological failures and neurological 
disorders in both DMD patients and animal models. These 
areas are in part overlapping with those recognized as major 
targets of GCs, which are released at high levels in response to 
both emotional and physical stressors. This makes imperative 
to better investigate whether the mode of action of GCs in the 
brain of wild type and dystrophic mice is similar, or whether 
important differences related to dysfunction of the DGC 
complex, determined by lack of Dp427, can be revealed. Since 
DMD patients are subjected to repeated and prolonged 
application of corticosteroids, directed at lowering recurrent 
muscular inflammatory events, it is of some importance 
identifying factors, which could aggravate the already 
compromised neurological conditions of young DMD patients.  
The first part of the project, conducted on wild type and 
mdx mouse hippocampal neurons in vitro, has been centered to 
uncover the response of these neurons, isolated from their 
physiological context and from other influence, to acute 
administration of different concentrations of CORT. 
 The second part of the project was performed by using 
an in vivo approach, and investigates the effect of acute and 
sub-chronic treatment with GCs on adult mdx and wild type 
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mice. CORT and DEX were used, respectively. In all 
experimental conditions, GR phosphorylation, expression, 
synthesis and cellular localization has been used as a marker of 
the response to GCs by hippocampus. This choice was based 
on the characteristic physiological regulation of GR levels by 
circulating GCs: GR modulation not only represents one of the 
first responses to GC, but it is also highly modulated by levels 
of circulating hormones and time of exposure. 
The final part of the research compares the effects of a 
sub-chronic exposure to DEX on the proliferation rate of NPCS 
localized in the sub-granular zone of adult wild type and mdx 
mice hippocampus. This quantitative study was performed by 
labelling dividing cells with green fluorescent EdU, injected 
intra-peritoneum alone or in combination with DEX. The 
dramatic impact on hippocampal physiology by elevated and/or 
persistent levels of GC, and the negative regulation they have 
on both NPCS proliferation and subsequent neurogenesis in 
healthy brains has been well cleared by several studies.  
The results obtained by this research highlights important 
aspects of the response of dystrophic mouse hippocampus, 
which could suggest future lines of research on the impact that 
GC-based therapeutic treatments have on the already 
compromised brain areas of DMD patients. 
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Materials and Methods 
  
Animals 
Wild type and genetically dystrophic mdx/mdx C57/Bl/10 mice 
(The Jackson Laboratory, Bar Harbor, Maine, USA) were used. 
All procedures were conducted in accordance with guidelines 
established by National Istitute of Health and in accordance 
with the Code of Ethics of the EU directive 2010/63/EU. The 
experimental protocols were approved by The Ethical 
Committee of Animal Research of the Italian Ministry of 
Public Health. 
Mice were housed in cages (max five per cage) and were 
maintained on a 12 h light–dark cycle with free access to food 
and water.  
 
Primary hippocampal neuron cell cultures 
Hippocampal neurons were cultured using reagents from 
Sigma-Aldrich (Milan, Italy), unless otherwise indicated. 
Briefly, hippocampi were dissected from embryonic day 18 
(E18) mice embryos in Ca2+- and Mg2+-free HBSS, containing 
3 mM HEPES (GIBCO, Milan, Italy) and antibiotics (100 
unit/ml penicillin and 0.1 mg/ml streptomycin). Hippocampi 
were washed 5 times in HBSS and then incubated, for 15 min 
at 37 °C, with 0.5 % trypsin and 100 µg/ml DNAse in Ca2+- 
and Mg2+-free HBSS, transferred in fresh HBSS and washed 5 
times. Dissociated cells were then obtained by mechanical 
dissociation, counted and plated on 35 mm Petri dishes (for 
Western blot, 1 x 106 cells per Petri dish) or on 12 mm glass 
coverslip (for immunofluorescence, 1 x 105 per coverslip), 
previously coated with 100 µg/mL poly-L-lisine (4 h at 37 °C) 
and 3 µg/mL laminin (overnight at 37 °C). Cells were grown in 
Neurobasal medium (GIBCO, Milan, Italy) containing 
antibiotics, B27 serum-free supplement (Invitrogen, Milan, 
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Italy), 0.5 mM glutamine and 23 µM glutamate,  for 14 days 
(14 DIV), in humidified atmosphere, at 37 °C with 5 % CO2  
In vitro glucocorticoid administration 
After 14 DIV, both wild type and mdx mouse hippocampal 
neurons were incubated for 1 h at 37 °C with either 1 µM or 10 
µM corticosterone (CORT) (Sigma-Aldrich), diluted in 
dimethyl sulfoxide (DMSO, Sigma-Aldrich) and glutamate free 
medium. Control cultures wee incubated with vehicle alone. 
Some of the cultures were, instead, incubated, for 1 h at 37 °C, 
with 10 nM dexamethasone (DEX) a more powerful GR 
activator, and used for immunocytochemical experiments (see 
the “Immunofluorescence in vitro” section)  
 
In vivo glucocorticoid administration 
Acute treatment. Six-seven week-old male wild type and mdx 
mice were randomly subdivided in three experimental groups: 
the CORT group (n=9/genotype), which received a single intra-
peritoneal injection of 40 mg/kg of CORT, diluted in saline and 
containing 15 % of hydroxypropyl-h-cyclodextrin (HBC; 
Sigma Chemical), 0.1 % dimethyl sulfoxide (DMSO) and 0.1 
% Tween-20; the vehicle group (VC) group (n=9/genotype), 
which was injected with vehicle alone; the control (CTRL) 
group (n=9/genotype), which was left untreated. Injections 
were delivered between 9:30 and 11:30 h. Mice were killed by 
decapitation after either 90 min or 6 h from injection, following 
Isoflurane (Merial, Milan, Italy) anaesthesia. In the case of 
mRNA and protein level evaluation, the hippocampi were 
rapidly dissected out and stored at –80 °C until use. Three 
mice/genotype of the CTRL and 90 min CORT groups were 
used for immunohistochemistry. In this case, mice were 
perfused as described in the appropriate section (see the 
“Immunohistochemistry” section). 
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Sub-chronic treatment: Six-seven weeks-old male wild type 
and mdx mice were randomly subdivided in three experimental 
groups: the DEX group (n=8 /genotype), which received a 
daily intra-peritoneal injection of 100 µg/kg dexamethasone 
(DEX) dissolved in saline as described by Kim et al. (161), for 
9 consecutive days; the VC group (n=8 /genotype), which was 
injected with vehicle alone; the CTRL group (n=4 /genotype), 
which was left untreated. Injections were always delivered 
between 9:30 and 11:30 h. Twenty four hours after the last 
DEX injection, mice were sacrificed by decapitation, as 
described for the acute treatment, hippocampi were rapidly 
dissected out and stored at -80 °C until use. 
Plasma corticosterone measurement 
Animals were euthanized by rapid decapitation in a benchtop 
fume hood. Trunk blood was collected into tubes, and samples 
were centrifuged at 3000 rpm for 20 min at 4 °C; sera were 
collected and stored at -80 °C until assayed. Plasma 
corticosterone was measured by specific radioimmunoassay. A 
single experimenter was responsible in acquiring all blood 
samples. CORT was measured in 5 µl plasma sample using a 
commercial radioimmunoassay (RIA) kit (ImmunChemTM 
125I Corticosterone RIA, MP Biomedicals, Orangeburg, NY) 
with 200 µl trace and 200 µl antibody as described by De 
Filippis et al. (168). The sensitivity of the assay was 7.7 ng/ml. 
All samples to be statistically compared were run in the same 
assay to avoid inter-assay variability. 
 
Real-Time PCR 
RNA extraction and retro-transcription 
Total RNA was extracted from both cultured neurons (n=10) 
and brain tissue (n=6/9) by using Directzol RNA MiniPrep Kit 
	 44	
(Zymo Research, Irvine, USA), following manufacturer’s 
instructions. Briefly, cell and tissue (a piece) samples were 
homogenated in 300 μl of TRIzol buffer, monophasic solution 
of phenol and isothiocyanate guanidine, and then was added the 
same volume of ethanol 100%. Each sample was transferred in 
a Zymo-Spin IIC spin column, within a 2ml collection tube, 
centrifuged at 10000 -14000 rpm for 1 min and the flow-
through was discarded. After rinse, was added at the column 
the Dnasi I, for 15 min at RT. Dnasi I was diluted in DNA 
digestion buffer 1:16. After digestion and rinse with Direct-zol 
RNA PreWash and RNA Wash Buffer, the column was 
transferred in a sterile tube and the RNA was eluted in 30 μl di 
Dnase/Rnase-Free Water.  RNA was quantified by using the 
Thermo Scientific NanoDrop 2000 spectrophotometer. 
Retrotrascription was performed using miScript II RT Kit 
(QIAGEN, Hilden, Germania). Mix solution was prepared into 
a sterile, nuclease-free tube (10% di miScript Nucleics Mix, 
20% di miScript HiFlex Buffer, 5% di miScript Reverse 
Transcriptase Mix), to which was added 150 ng of RNA 
sample template. Samples were gently mixed and incubated for 
60 min at 35 °C. The reaction was blocked by heating samples 
at 70 °C for 5 min.  
 
Quantitative RT-PCR 
For each sample, were amplified 10 ng di cDNA (QuantiTech 
fast SYBR Green PCR Kit, Quiagen) using mix solutions 
composed by 2X QuantiTech SYBR Green PCR Master Mix 
and 10X QuantiTech Primer Assay in ultrapure water. Three 
technical repetitions have been made for each primer. cDNA 
was amplified at 95 °C for 15 min, 94 °C for 15’’, 55 °C for 
30’’, 72 °C for 30’’, 95 °C for 15’’, and finally a melting phase 
at 65-95°C for 15’’ in a 7500Fast real-time PCR (Applied 
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Biosystem). Total number of cycles was 40. Primers pairs 
sequences are shown below: 
Eif1α: Mm_Eif1_1_SG QuantiTect (QT02280348 Qiagen, 
Germany) GR: Mm_Nr3c1_1_SG QuantiTect (QT00160349 
Qiagen, Germany) Dsip: Rn_Tsc22d3_1_SG QuantiTect 
(QT00404075 Qiagen, Germany) ATP50: 
CAACCGCCCTGTACTGTGCT (fw) and 
GGATTCAGAACAGCCAGAGACAC (rw);   
 
Western Immunoblot 
Primary antibodies  
Antibodies used for Western Immunoblot were: rabbit anti-GR 
(D6H2L), rabbit anti-pGR-Ser 211, rabbit anti-p44/42 MAPK 
(Erk1/2), rabbit anti-phospho-p44/42 MAPK (pErk1/2 
Thr202/Tyr204) and rabbit anti-caveolin1 (Cav1), were from 
Cell Signaling Technology (Leiden, Netherlands) and diluted 
1:1000 in 5 % BSA (Bovine Serum Albumin), 0.1 % Tween 20 
in TBS (Tris Buffered Saline) 1X. Mouse anti-caveolin2 
(Cav2) (1:500; BD Transduction Laboratories, Milan, Italy), 
rabbit anti-b-actin (1:1000; AbCam, Cambridge, UK), and 
mouse anti-GAPDH (Glyceraldehyde Phosphate 
Dehydrogenase) (1:5000; AbCam, Cambridge, UK), were 
diluted in 3 % BSA, 0.1 % Tween20, 0.05% NaN3 in TBS 1X. 
 
Preparation of cell lysates and tissue extracts 
Cell lysates were obtained from hippocampal neuron cultures 
(106/Petri dishes) (n=3/genotype/treatment). After removing the 
culture medium, neurons were washed with PBS and Petri 
dishes placed on ice. Cells were lysed with 50 µl RIPA buffer 
(50 mM Tris/HCl pH 7.6, 150 mM NaCl, 1 mM EDTA, 1 % 
SDS, 1 % Triton X-100, 10 µl/ml cocktail of protease 
inhibitors, 1 mM PMSF, 0.2 mM Na3VO4 and 1 mM NaF), 
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applied for ~5 min before scraping cells and transferring them 
in a 1.5 ml tube. 
Tissue extracts were obtained from six-seven weeks-old male 
wild type and mdx mouse hippocampi (n=6-
9/genotype/treatment) previously stored at -80 °C. A piece of 
tissue was placed in 400 µl of RIPA buffer and sonicated for 30 
sec at a frequency of 30 kHz in an UP100H Ultrasonic 
Processor (Dr. Hielsher GmbH, Teltow, Germany). 
 
Electrophoresis 
Both cell lysates and tissue extracts were centrifuged at 14000 
rpm for 15 min at 4 °C and a measured aliquot of the 
supernatant was used to determine protein concentration by 
using Micro BCA Kit (Pierce, Rockford, IL, USA). Loading 
buffer (4X: 200 mM Tris/HCl pH 6.8, 4% SDS, 30% glycerol, 
4% b-mercaptoethanol, 4% blue bromophenol) was added to 
the homogenates to a final 1X concentration. Twenty µg of 
protein of hippocampal neuron lysates and twenty five µg of 
hippocampal tissue homogenates were electrophoresed at 4 °C 
on a 10% SDS–PAGE gel (25 mA for each gel) in running 
buffer (Tris 25 mM, Glycine 192 mM, SDS 0,1% in distilled 
water) along with a pre-stained molecular weight markers 
(AbCam, Cambridge, UK) (245 KDa, 180 KDa, 135 KDa, 100 
KDa, 75 KDa, 63 KDa, 48 KDa, 35 KDa, 25 KDa, 20KDa, 17 
KDa, 11 KDa) and then transferred onto a nitrocellulose 
membrane (2 h, RT at 70 V) by using a transfer buffer made of 
Tris 50 mM, Glycine 380 mM, SDS 0.1%, Methanol 20 % in 
distilled water. 
Protein revelation 
Membranes were first incubated, for 2h at RT, in 5% dry milk 
(DM) in 1X TTBS (20 mM Tris HCl, pH 7.4; 500 mM NaCl; 
	 47	
0.05 % Tween20), to block non-specific binding sites, and then 
with either of the primary antibodies, overnight at 4 °C. After 
thorough rinse in buffer, membranes were incubated for 1h at 
RT in either anti-rabbit IgG or anti-mouse IgG secondary 
antibody, conjugated with horseradish peroxidase (HRP), 
diluted 1:5000 in 2.5 % DM in 1X TTBS. Antibody binding 
sites were detected by chemiluminescence (ECL) 
(Immunological Science) using luminol/peroxidase detection 
reagents. The intensity of the bands was evaluated by 
densitometric analysis using the ImageJ Software. The optical 
density (OD) of each protein band was normalized against the 
OD of actin or GAPDH bands, used as internal reference 
standards. 
 
Immunofluorescence in vitro 
Control CORT- and DEX-treated hippocampal cell cultures (n= 
3 per genotype and treatment) were immunolabelled for GR, 
pGR and cleaved Caspase-3. Control and glucocorticoid-
treated cultures (CORT and DEX) were washed in PBS and 
then fixed in 4% paraformaldehyde and 4 % sucrose in PBS, 
for 10 min at RT. After a rinse (3 x 10 min) in PBS, cells were 
incubated in the blocking solution [1 % BSA, 10 % NGS 
(Jackson Immuno Research, Suffolk, England) and 0.5 % 
Triton X-100 in PBS] for 1h at RT. Primary antibodies, rabbit 
anti-GR (1:1000), rabbit anti-pGR (1:1000), anti-caspase 3-
cleaved (1:300) (Cell Signaling Technology, Leiden, 
Netherlands) and mouse anti-NeuN (1:100) (Millipore, 
Darmstadt, Germany) were diluted in 1 % BSA, 1 % NGS, 0.2 
%Triton X-100 in PBS and incubated overnight at 4 °C. After a 
rinse (3 x 10 min) in PBS, cultures were incubated with the 
appropriate secondary antibody, either goat anti mouse IgG 
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Alexa Fluor 488 (Molecular Probes, Invitrogen), or goat anti 
rabbit IgG Cy3 (Jackson Immuno Research) diluted 1:1000 and 
1:800, respectively, for 1h at RT. After a rinse in PBS (3 x 10 
min), cell cultures were incubated in the nuclear stating 
Hoechst 33342 (Invitrogen, Carlsbad, CA), 1:10000 in PBS 
rinsed again (3 x 10 min) and mounted on glass slides with the 
ProLong Gold Antifade Reagent (Invitrogen). Cultures were 
viewed at an optical microscope (AxioScop2, Carl Zeiss, Jena, 
Germany) photographed with a video camera (AxioCam MRc5	
Carl Zeiss, Jena, Germany), by using the AxioVision 4.8.2 SP3 
software. Images were adjusted for brightness and contrast with 
the Photoshop software for aesthetic purposes only. GR and 
pGR immunofluorescence was analysed for intensity and 
localization, while caspase-3 immunopositive neurons were 
photographed at a 63X oil objective (Carl Zeiss, Jena, 
Germany) and counted. The percentages of apoptotic neurons 
after CORT treatment in both wild type and mdx mouse neuron 
culture were statistically analysed by the c2 – test. 
 
EdU incorporation and detection 
Six-seven weeks-old male wild type and mdx mice, sub-
chronically injected with either DEX or saline, received from 
day 6 to day 9 (in combination 
with DEX or saline) (Fig 8) a 
daily intraperitoneal injection 
of 50 mg/kg b.w. of 5-ethynyl-
2’-deoxyuridine (EdU, The 
Click-iT® EdU Assay, 
Invitrogen, Carlsbad, CA).  
EdU was dissolved in 0.9 % 
NaCl and 0.1 % DMSO and 
filtered through a 0.2 µm 
Fig. 8:  Schematic representation of 
Dex and EdU treatment plan 
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syringe filter, in sterile conditions. Mice (n=4 /genotype) were 
sacrificed 24 h after the last DEX and EdU injections. Mice 
were deeply anesthetized with a mixture of Zoletil-100 (20 
mg/Kg b.w.; Virbac, France) and Rompun® (8 mg/Kg b.w.; 
Bayer, Canada), diluted in saline, and perfused via the 
ascending aorta with a Ringer solution 1X (10X: 85g NaCl, 
2.5g KCl, 2g NaHCO3 per 1 l), followed by ~ 100 ml of 
fixative composed of freshly depolymerized 4% 
paraformaldehyde in 0.1 M phosphate buffer. Brains were 
rapidly removed, cryoprotected for 2-3 d in a 30 
%sucrose/saline solution, frozen on dry ice and stored at 80 °C 
until use. Coronal serial sections (30 µm/section) were cut at a 
freezing microtome (Leica), through the entire antero-posterior 
extension of the hippocampus, and collected free floating. Part 
of the series were immediately mounted on glass slides, while 
unused series were placed in an anti-freezing solution (NaCl 
150 mM, PVP-40 250mM, Ethylene glycol 30%, Sucrose 
50mM in PB 0,1 M) and stored at -80 °C until use. Sections 
were permealised with 0.5 % Triton X-100 in PBS for 20 min, 
rinsed twice in 3 % BSA in PBS, and then incubated for 30 min 
at RT and in the dark, with the Click-iTTM reaction cocktail 
containing: Click-iTTM reaction buffer, CuSO4, Alexa Fluor® 
488 Azide, and reaction buffer additive. Successively, sections 
were rinsed in 3 % BSA in PBS and incubated with 5 μg/mL 
Hoechst 33342 in PBS, for 30 min, to allow nuclear staining. 
Slides were finally washed twice in PBS and coverslipped with 
the Prolong Gold Antifade Reagent mounting media.  
 
Cell counting and statistical analysis 
Hippocampi were viewed and photographed with a video 
camera at a Zeiss (AxioScop2, Carl Zeiss, Jena, Germany) 
fluorescent microscope, with a 20X objective, which allows 
including one entire hemi-hippocampus. EdU-positive cell 
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(EdU+) were counted at the dentate gyrus (DG) level by using 
the Image J software: briefly, the DG area, evidenced by the 
Hoechst staining (as reported in Fig. 
9), was manually outlined in one out 
of 5 brain sections (150 µm apart), 
throughout the entire hippocampus. 
EdU+ cells were counted in the focal 
plane in which they appeared at their 
largest size, within the traced area, 
and final values were expressed as the 
number of EdU+ cells/DG volume. 
DG reference volume was determined 
by summing the traced DG areas of 
each section and multiplying this number by the distance 
between the chosen sections. 
 
Peroxidase anti-peroxidase immunohistochemistry 
Primary antibodies 
Primary antibodies used for immunohistochemistry were: 
rabbit anti-GR (1:800) rabbit anti-pGR-Ser 211 (1:500) 
 
Immunostaining 
Control and 90 min CORT-injected wild type and mdx (n=3 
/genotype/treatment) were perfused, as described above, with 
4% freshly depolymerized paraformaldehyde in 0.1 M PB. 
Brains were dissected out, cryoprotected in 30 % sucrose in 
saline, for 2-3 days at 4 °C, and then cut at a freezing 
microtome in serial sagittal section (30µm), collected free 
floating in 0.1 M PB. Endogenous peroxidases were blocked by 
incubating sections, for 10 min at RT, with 10 % methanol, 3 
% H2O2 in Tris 0.5 M pH 7.6. After 3 x 5 min rinses in buffer, 
sections were first incubated in 5 % DM, 0.5 % Triton X-100 
in 0.1 M PB for 1h at RT, to block unspecific labelling, and 
Fig 9:	 representative 
image of DG area, 
manually outlined by 
using Image J software. 
Scale bar: 100 µm  
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then with one of the primary antibodies, appropriately diluted 
in 1 % DM, 0.2 % Triton X-100 in 0.1 M PB, for two 
overnights 4°C. After a rinse (3 x 10 min) in 0.1 M PB, 
sections were incubated, for 1 ha at RT, with a secondary 
antibody raised in goat and directed against the IgG of the 
animal species in which the first antibody was raised: Goat 
anti-Rabbit IgG (1:100) or goat anti-mouse IgG (1:100) 
(Covance, Princeton, NJ, USA). After further rinses in 0.1 M 
PB (3 x 10 min), sections were incubated with the tertiary 
antibody raised in the species of the primary antibody and 
directed against the enzyme peroxidase. These formed 
complexes, called peroxidase-anti-peroxidase (PAP), which 
amplified the signal: rabbit PAP (1:100) and mouse PAP 
(1:100). After 3 x 10 min rinses in buffer, antibody binding 
sites were revealed by a 10 min incubation, in the dark at RT, 
in 0.05 % 3-3’-diaminobenzidine (DAB; Sigma) and 0.01 % 
H2O2 in 0.1 M PB. After a thorough final rinse, sections were 
placed on glass slides and mounted with Eukitt balsam. 
Sections were viewed at a Zeiss AxioScop2 light microscope 
and images acquired by a video camera, using the AxioVision 
4.8.2 SP3 software. 
 
Statistical Analysis 
Unless differently indicated, all data were analysed by the two 
tails Student’s t-test. Differences were considered statistically 
significant for p £ 0.05. Data are expressed as a mean ± 
standard error of the mean (SEM). 
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Results 
 
In vitro treatments 
To evaluate the response of wild type and mdx mouse 
hippocampal neurons to acute GC administration, devoid of 
other systemic influences, primary neuron cultures were 
obtained from both genotype hippocampi and grown for 14 
days. Either 1 µM CORT, 10 µM CORT or vehicle alone 
(DMSO) were added for 1 h to culture media, and cells 
incubated for 1 h in incubator (37°C, 5% CO2). Modulation by 
GCs on GR activation (protein levels of phosphorylated GR), 
synthesis (protein levels of total GR) and expression (mRNA 
levels) were evaluated. 
 
GR protein levels in the hippocampus of E18 mdx mice are 
significantly lower compared to wild type 
GCs are present in both maternal and foetal circulation and, in 
most species, increase in concentration towards term (169). In 
general, GC concentrations are higher in the mother than the 
foetus, and maternal GCs enter the placenta blood stream and 
reach the foetus. In mice, for example, 70–80 % of the 
circulating GCs in foetuses is of maternal origin, as foetal 
adrenal cortex is relatively inactive, or incapable of 
steroidogenesis (170). Environmental stressors, which raise 
maternal GC levels, also increase foeto-placental GC exposure 
(169). GCs can, therefore, cross the placenta in both directions, 
depending on the concentration gradient, and their 
bioavailability is modulated by the tissue 11β-hydroxysteroid 
dehydrogenase (11β-HSD) activity (171). In foetuses, GCs 
have even a broader range of functions, during both normal and 
adverse conditions, than adults (172). Towards term, they act as 
the primary maturational signal in the developmental sequence 
that prepares the foetus for the new challenges of extra uterine 
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life. However, by changing foetal tissue development, early 
exposure to excess glucocorticoids modifies the phenotype, 
with life-long physiological consequences (173). Based on 
these assumptions, we evaluated the baseline levels of GR and 
pGR in E18 mice hippocampi, the pre-natal date at which 
hippocampal cell cultures were prepared. This at the aim to 
ascertain whether there was already an ongoing modulation of 
the two protein levels consequent to recurrent mild 
inflammatory events occurring in DMD mice. As shown in Fig 
10A, A’, total GR protein levels in mdx mice were significantly 
lower compared to wild type, while no differences were present 
in the pGR protein levels. However, by comparing the ratio of 
pGR/total GR in each genotype, a higher proportion of GR is 
phosphorylated in mdx mouse neurons compared to wild type. 
 
 
Fig 10. GR and pGR protein levels in E18 wild type and mdx mouse 
hippocampus. A: representative Western immunoblots of GR and pGR 
proteins in E18 wild type and mdx mice. A’: Corresponding densitometric 
analyses. Data are represented as the mean ± SEM of the optical densities 
(O.D.) of the GR and pGR immunopositive bands. Data are analysed by the 
two tails Student’s t-test. n = 4 independent experiments. *p ≤ 0.05 WT vs 
mdx. 
 
This difference may reflect a classical behavioural response of 
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the hippocampus to elevated, or long-lasting, exposure to GCs, 
which induce down-regulation of receptor expression/synthesis. 
To explore the hypothesis that this difference was due to 
elevated CORT levels in mdx pregnant mothers compared to 
wild type, one preliminary CORT radioimmunoassay (RIA) 
experiment, using trunk blood samples, has been performed. As 
expected from literature data (174) this first experiment showed 
high CORT levels in the wild type female mice (1275,248 
ng/ml), due by enhanced activity of HPA axis after mid-
gestation in healthy condition. CORT levels in the mdx 
pregnant female were higher (1669,903 ng/ml) than wild type, 
possibly due mild muscular degeneration also occurring in mdx 
female mice. This data, however, need to be confirmed and 
statistically analysed by further experiments.   
 
GR and pGR protein levels after acute corticosterone treatment  
GCs act on target cells by binding to both cytoplasmic and 
membrane receptors, and this binding determines receptor 
phosphorylation, which indicates its activation (77). 
Phosphorylation, which occurs mainly at Ser211, correlates 
with the GR transcriptional activity (68). As reported in Fig 
11A’, a significant increase in pGR levels was observed solely 
in wild type mouse neurons after 1 µM CORT treatment, 
compared to vehicle treated neurons. At this concentration, mdx 
mouse hippocampal cells showed just a tendency to increase 
pGR levels compared to vehicle, but this difference never 
reached significance. No differences were observed, for both 
genotypes, when neurons were treated with 10 µM CORT. 
Representative Western immunoblot are shown in Fig. 11A 
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Fig 11: pGR and GR protein levels, and modulation of GR gene 
expression after 1 h CORT treatment.  
A and B: representative Western immunoblots of pGR and GR protein 
levels in lysates from wild type and mdx E18 hippocampal neurons, cultured 
for 14 days and treated either with vehicle (VC), 1 µM CORT or 10 µM 
CORT. A’ and B’: Corresponding densitometric analyses. Data are 
represented as the mean ± SEM of the optical densities (O.D.) of the bands 
immunopositive for pGR and total GR. C: relative gene expression of the 
GR gene 1 h after vehicle and CORT treatments. Data are represented as the 
mean ± SEM of the relative gene expression. All data were analysed by the 
two tail Student’s t-test. n = 10 independent experiments. *p ≤ 0.05; **p ≤ 
0.01; ***p ≤ 0.001 vs VC. 
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GR activation is associated with the modulation of its own 
expression, and this event is thought to be involved in the 
negative feedback mechanism that the hippocampus plays on 
the HPA axis and hence, on GCs synthesis and release (175).	
Total GR protein levels were, then, analysed. As shown in the 
representative Western immunoblot (Fig. 11B) and 
corresponding densitometric analyses (Fig. 11B’), acute 
administration of 1 µM of CORT to wild type neurons induced 
a significant increase in the total GR levels, compared its 
respective control vehicle. In contrast, mdx mouse neurons 
underwent a significant reduction in GR levels. Once again, 
high CORT concentration (10 µM) did not induce changes in 
GR levels, for both genotypes.  
 
GR mRNA levels are differently modulated in wild type and 
mdx mouse hippocampal neurons after acute treatment with 
high CORT concentrations 
As expected following a genomic response to acute GR 
activation (176), GR mRNA levels in the wild type mouse 
neurons, evaluated by real time RT-PCR, increased in a CORT 
dose-dependent manner compared to vehicle (Fig. 11 C), 
although with a high variability at the 10 µM concentration. 
Differently, in mdx mouse neuron culture, a slight, but 
significant, increase was observed only after 1 µM incubation, 
whereas a significant reduction was observed when 10 µM 
were used (Fig. 11C). 
These results suggest that, despite GR phosphorylation, 
dystrophic mouse neurons do not respond as a to a classical 
acute receptor activation, as wild type mouse neurons do. 
Instead, type of response resembles more what could be 
expected following a chronic administration, which 
progressively inverts the outcome of the genomic response, 
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inhibiting GR activity in hippocampal neurons more than 
promoting it. 
 
Acute administration of high corticosterone concentrations 
promotes neuronal death 
From these first results, appeared clear that, even in wild type 
mouse neuron cultures, the response to elevated CORT 
concentrations did not induce an increase in the levels of both 
pGR and GR, suggesting the 10 µM concentration could be 
lethal for cultured neurons, because not physiological (177). 
Therefore, to investigate this aspect, we conducted a 
quantitative study on the number of apoptotic neurons present 
in the three experimental conditions, by immunolabelling 
hippocampal neuron cultures for caspase 3-cleaved (Casp 3), a 
common apoptotic marker (Fig. 12A).  
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Fig 12. Quantitative analysis of apoptotic neurons in VC and CORT 
treated hippocampal neuron cultures. A: representative images of 14 
DIV hippocampal wild type and mdx neurons from E18 mouse embryos, 
incubated for 1 h with either vehicle (VC), 1 µM CORT or 10 µM CORT. 
Neurons were co-immunolabelled for caspase 3-cleaved (Casp 3, red), an 
apoptotic marker, and NeuN (green), a neuronal marker. Nuclei were 
stained with the Hoechst nuclear dye (blue). B: quantitative analysis of 
caspase+ cells in the three conditions. Data are represented as the mean 
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percentage of apoptotic neurons ± SEM, and analysed by the c-squared test. 
N = 10 independent experiments. ***p ≤ 0.001 vs CTRL; §§§p ≤ 0.001, 1 
µM vs 10 µM within the same genotype.	
 
The percentage of apoptotic neurons after both 1 µM 
and 10 µM CORT incubation significantly higher compared to 
the respective control, in both genotypes [wild type: 26 % (VC) 
vs 38 % (1) vs 45 % (10); mdx: 30 % (VC) vs 35 % (1) vs 46 % 
(10)], with a significant increase intra-genotype between the 1 
µM and 10 µM conditions (Fig. 12B). These results confirmed 
the hypothesis that acute CORT treatment increases the 
physiological apoptotic activity of hippocampal neurons 
consequent to culturing procedures, an increase that at the 10 
µM concentration doubles the number observed in control 
conditions.  
 
Immunofluorescence analysis confirms glucocorticoid effects 
on hippocampal neurons disclosed by biochemical analyses 
As described in the previous section, wild type and mdx mouse 
hippocampal neurons respond differently to acute 
administration of CORT. To further verify these results, we co-
immunolabelled vehicle, 1 μM CORT and 10 nM DEX-treated 
hippocampal neurons for tubulin bIII (Tuj1; a neuronal marker) 
with either pGR or GR. DEX is a synthetic, specific and potent 
analogue of GCs, which we used as a positive control of 
hippocampal response to CORT treatment. Immunolabelling 
revealed a prevalent localization of GR within the nucleus, in 
all experimental conditions (Fig. 13). In wild type hippocampal 
mouse neurons, both intensity of immunolabelling and number 
of labelled nuclei increased slightly after both treatments, being 
somewhat more intense after 1 h DEX incubation. Differently, 
labelling in mdx mouse neuron culture remained apparently 
unchanged after GC treatment. Immunolabelling for pGR (Fig. 
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14), instead, was both nuclear and cytoplasmic, labelling cell 
somata and neurites, and often associated to the plasma 
membrane (enlargement in Fig. 14). In wild type mouse 
hippocampal neurons, the intensity of pGR immunolabelling 
increased after both treatments, being more intense after DEX 
incubation. Differently, in mdx mouse hippocampal neurons, 
the increase in pGR intensity of immunolabelling after both 
incubations was less prominent compared to wild type.  
This data confirms the previously obtained biochemical 
results. 
 
 
Fig 13. Qualitative analysis of GR intensity of immunolabelling in 
vehicle, CORT and DEX-treated hippocampal neuron cultures. 14DIV 
wild type and mdx mouse hippocampal neurons from E18 embryos are co-
immunolabelled for βIII tubulin (Tuj1, green) and GR (red). GR 
immunofluorescence is prevalently localized within cell nuclei, in all 
experimental conditions: vehicle (VC), 1 μM CORT and 10 nM DEX. Both 
GC treatments induce a slight increase in the intensity of immunolabelling 
only in the wild type mouse neuron cultures. Nuclei are stained the Hoechst 
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dye (blue). Scale bar: 30 μm.  
 
 
 
Fig 14. Qualitative analysis of pGR intensity of immunolabelling in 
vehicle, CORT and DEX-treated hippocampal neuron cultures.14DIV 
wild type and mdx mouse hippocampal neurons from E18 embryos are co-
immunolabelled for βIII tubulin (Tuj1, green) and pGR (red). pGR 
immunofluorescence is localized within cell nuclei, somata and along 
neurites, often associating with the plasma membrane (arrows in the 
enlargement), in all experimental conditions: vehicle (VC), 1 μM CORT and 
10 nM DEX. The intensity of immunofluorescence increases after both GC 
treatments; however, this increase in more evident in the wild type mouse 
neuron cultures compared to those from mdx mice. Scale bar: 30 μm; 
enlargement: 10 μm.  
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In vivo treatments 
In healthy individuals, increase in GC synthesis and release 
follows the coordinated activation of the neuroendocrine HPA 
axis and the autonomic nervous system by both emotional and 
physiological stressors. The ubiquitous expression of GC 
receptors and the multiple functions of GCs confer this system 
a central role in the stress response towards homeostasis 
restoration. Autonomic and limbic circuits (e.g. amygdala, 
hippocampus) as well as the medial prefrontal cortex, strictly 
regulate HPA axis activity, as chronic exposure to GCs results 
in various adverse side effects. In the previous section of the 
results we showed that hippocampal neurons of mdx mice 
respond differently from wild type to acute CORT treatment in 
vitro, mimicking what has been reported to be a response to 
chronic exposure. However, if from one side neuron cultures 
were optimal for investigating, in a clean and controlled 
manner, fine intracellular responses to GC administration, an in 
vivo approach would give precious information on the 
structural plasticity to which these neurons undergo while 
included in their proper circuits. At this aim, adult wild type 
and mdx male mice (6-7 weeks-old) have been subjected to: a) 
acute treatment with CORT (one intraperitoneal injection of 
either 40 mg/Kg of CORT) and sacrificed after 90 min; b) 
acute treatment with CORT and sacrifice after 6 h; c) sub-
chronic treatment with DEX (one intraperitoneal injection/day 
of 100 µg/kg of DEX, for 9 days) and sacrificed 24 h after the 
last DEX injection. Control mice of both genotypes received 
acute or sub-chronic injections of the corresponding vehicles. 
The hippocampi were dissected and processed for molecular 
biology (analysis of GR and GILZ mRNA levels), 
biochemistry (analysis of GR, pGR, ERK, pERK, Cav1 and 
Cav2 protein levels). Part of the mice sacrificed after 90 min 
have also been perfused with opportune fixatives and brains 
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processed for immunohistochemistry for GR and pGR.  
The choice to analyse two time points after the acute 
treatment aimed at uncovering possible differences between 
short- and long-term responses after acute treatments. 
 
Ninety minutes after acute corticosterone treatment, GR 
protein levels are differently modulated in wild type and mdx 
mouse hippocampal neurons 
As expected, 90 min after a single CORT injection, the pGR 
protein levels increased significantly compared to control, in 
both wild type and mdx mouse hippocampus, indicating that at 
this early time point GR has been activated (Fig 15A, A’). 
However, in mdx mouse extracts, pGR levels tended to increase 
also in the vehicle treated hippocampi, although they did not 
reach statistical significance. On the contrary, in wild type mice 
GR protein levels remained stable, as expected since 90 min in 
vivo is a time still too short to see eventual genomic effects. 
Differently, GR protein levels significantly decreased, 
compared to control, in both vehicle and CORT-treated groups 
of mdx mice (Fig 15B, B’), In addition, levels in these two 
groups were perfectly comparable, complying what has been 
reported by the literature on a peculiar susceptibility of mdx 
mice to stressors (178), which in this case could be both 
injection and the experimenter grasp and manipulation. 
Interestingly, the possible synergy between endogenous and 
exogenous GCs in the CORT group does not induce a stronger 
response compared to the vehicle group, suggesting that the 
system could be considered as "saturated", similar to sub-
chronic or chronic conditions.  
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Fig 15.	 Hippocampal	 pGR and GR protein levels 90 min after acute 
CORT treatment. A and B,	 representative Western immunoblots of pGR 
and GR protein levels in the hippocampus of wild type and mdx mice either 
untreated (CTRL) or acutely injected with vehicle (VC) or CORT. A’ and 
B’,	Corresponding densitometric analyses. Data are represented as the mean 
± SEM of the optical densities (O.D.) of the bands immunopositive for pGR 
and total GR and analysed by the two tail Student's t-test. n = 9 independent 
experiments. **p ≤ 0.01 vs CTRL; §p ≤ 0.05 vs VC. 
 
 
Modulation of hippocampal GR and GILZ mRNA after 90 min 
from acute corticosterone treatment are different between wild 
type and mdx mice 
Relative gene expression of GR and GILZ (the protein encoded 
by Dsip gene) were evaluated, by real-time RT-PCR, in the 
three experimental conditions, as indication of a genomic 
response to the acute CORT treatment. GILZ is a transcription 
factor important in the regulation of inflammatory responses, 
and is one of the early target genes of the nuclear pGR (179).	
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For this reason, its expression was used, along that of the GR 
gene, as an indicator of GR-mediate transcriptional activity. In 
wild type mouse hippocampus, GR mRNA levels did not 
change significantly, with respect to control, 90 min after either 
vehicle or CORT injection. Differently, in both experimental 
groups, GILZ mRNA levels were significantly up-regulated, 
suggesting an extreme reactivity to treatments (Fig. 16). 
Conversely, in mdx mouse hippocampi, the only difference 
compared to control animals was a significant reduction in the 
GR mRNA levels after CORT injection, suggesting an early 
de-regulation of the GR expression (Fig. 16). 
 
 
 
Fig. 16. Hippocampal GR and GILZ mRNA levels 90 min after acute 
CORT treatment. GR and GILZ mRNA levels were evaluated by real time 
RT-PCR in the hippocampus of control (CTRL), vehicle (VC) and CORT 
injected wild type and mdx mice. Data are represented as the mean relative 
expression ± SEM. n = 9 independent experiments. **p ≤ 0.01; ***p ≤ 
0.001 vs CTRL. 
 
Immunohystochemical analysis of pGR and GR localization 
GR and pGR localization at the hippocampal levels before and 
after acute CORT treatment was also investigated by 
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immunohistochemistry with the immuno-enzymatic peroxidase 
anti-peroxidase method. 
In CTRL conditions, GR immunoreactivity is intense in 
both wild type and mdx mouse hippocampus, with a marked 
distribution within the DG and CA1 hippocampal regions, 
while the CA3 region is only faintly labelled (Fig. 17). Ninety 
minutes after CORT treatment, GR distribution did not change, 
but the intensity of immunolabelling in the DG appeared lower 
compared to control, especially in the hippocampus of mdx 
mice. Differently, basal levels of pGR immunolabelling in 
control condition was extremely faint, in both genotypes, with 
immunopositive cells mainly localized in a zone within the 
posterior portion of the CA1 region. Ninety minutes after acute 
CORT administration, the distribution of pGR immunopositive 
neurons did not change, but the intensity of immunolabelling 
increased visibly in both genotypes, although appeared a bit 
more intense in the wild type mice (Fig. 17). 
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Fig 17: GR and pGR immunohistochemistry on mouse brain sagittal 
sections. GR and pGR immunolabelling was performed on control (CTRL) 
and CORT injected wild type and mdx mice by using the PAP method. 
Scale bar: 100 µM. 
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Analysis of the levels of proteins involved in the rapid non-
genomic signalling mediated by glucocorticoids 90 min after 
acute corticosterone treatment 
As previously mentioned, the rapid non-genomic GR signalling 
activates cellular signal pathways, active at various levels, 
including that of gene expression through its interaction with 
the GR genomic path. More precisely, its activation recruits 
proteins of the MAPK family, including the activation of 
ERK1/2, which operate both within the cell cytoplasm and 
nucleus, where they regulate the expression of target genes 
(97). This pathway seems to be finely modulated by the mGRs,	
which interact with caveolins, proteins component of lipid rafts 
(180) that, in turn, regulate both structure and function of these 
membrane micro-domains. Cav1 is also important for GR 
proper activation and for the recruitment of proteins 
downstream its signalling (97). An interesting aspect is that 
Cav1 could be stabilized within the membrane by the Dp427-
DGC. It was therefore, important to investigate the effects of 
acute CORT administration also on this non-genomic pathway. 
Ninety minutes after a single CORT or vehicle injection, 
Cav1 level were significantly increased, in CORT experimental 
group of wild type mice compared to vehicle and control mice. 
On the contrary, Cav1 protein levels did not significantly 
change in mdx mouse hippocampus, compared to their 
respective controls (Fig. 18A, A’), suggesting a signal de-
regulation, possibly consequent to excessive levels of 
endogenous GC and/or GR destabilization. 
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Fig 18. Hippocampal	Cav1, ERK and pERK protein levels 90 min after 
acute CORT treatment. A, B, C: representative Western immunoblots of 
Cav1, pERK and ERK protein levels in the hippocampus of wild type and 
mdx mice either untreated (CTRL), or acutely injected with vehicle (VC) or 
CORT. A’, B’, C’:	 corresponding densitometric analyses. Data are 
represented as the mean ± SEM of the optical densities (O.D.) of the bands 
immunopositive for each protein and analysed by the two tail Student's t-
test. n = 5 independent experiments. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001 vs 
CTRL; §p ≤ 0.05 vs VC.  
 
ERK 1/2 and its phosphorylated form is one of the best-
known mediators of the non-genomic mGR pathway. After 
	 71	
acute CORT treatment, a significant increase in pERK and total 
ERK protein levels were observed only in the wild type mouse 
hippocampus (Fig. 18B, C), suggesting a prompt activation of 
this pathway in response to GCs (86). No changes were, 
instead, observed after treatments (CORT and/or vehicle) 
neither in the levels of pERK nor on those of total ERK 
proteins in mdx mice (Fig 18B, B’, C, C’).  
Any situation perceived as potentially aversive will stimulate 
the amygdala-sympathoadrenal and hypothalamic-pituitary-
adrenal (HPA) axis to increase plasma and brain levels of 
glucocorticoids (181). This physiological reaction to stressors 
results in enhanced arousal, appraisal, autonomic and cognitive 
performance in response to both prompt threat and 
vulnerability (182). Nevertheless, in terms of animal assays, a 
number of variables such as cage density, luminosity, time of 
the day, noise level, diet, animal handling and manipulation 
greatly affect sensitivity in stress assays (183, 184). To 
evaluate the effects of manipulation and injection in both 
genotypes, we performed one preliminary corticosterone RIA 
on trunk blood samples from adult male wild type and mdx 
mice either acutely injected with vehicle or not-injected. These 
very first data suggest an opposite trend between two 
genotypes: in wild type mice, vehicle injection seems to induce 
a decrease in CORT levels compared to control (control: 
334,29 ng/ml; vehicle: 159,50 ng/ml). Differently, control mdx 
mice have blood CORT levels (104,56 ng/ml) close to those of 
vehicle injected wild type mice, suggesting a pre-existing 
“stressful” conditions, probably due to chronic muscles 
inflammation and functional hippocampal alterations. Vehicle 
injection increased CORT levels (340,94 ng/ml), suggesting 
that an increased stressful condition impacts hippocampal 
negative regulation of the HPA axis, as reported in the 
literature (110, 111). This very preliminary result, to be 
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confirmed and statistically analysed, reinforces the observation 
of an intrinsic high susceptibility of vehicle treatment, 
especially for mdx mice. 
 
Six hours after acute corticosterone treatment, GR protein 
levels are differently modulated in wild type and mdx mouse 
hippocampal neurons 
As previously stated, GCs induce both a rapid non-genomic 
response via membrane receptors 
and a slow, persistent genomic 
response via cytoplasmic/nuclear 
receptors (Fig. 19). Corticosteroid 
hormone levels in the brain are 
raised with a delay of approximately 
20 min, compared to the rise 
observed in the plasma (185), and 
return to baseline after 1-2 h. Based 
on the data obtained after 90 min 
from acute CORT administration, we 
investigated long-term effects after a 
single CORT injection. At this aim, 
wild type and mdx mice were sacrificed 6 h from acute CORT 
or vehicle treatment, and brain tissue was prepared for 
biochemical and molecular analysis. 
As expected, after 6 h, levels of hippocampal pGR for 
both genotypes were similar to control, in both vehicle and 
CORT treated groups (Fig. 20A, A’), indicating that at this 
time receptors are not anymore activated. Differently, GR 
protein levels increased in the CORT-treated groups of wild 
type animals, suggesting either a positive control of its 
synthesis, or a decrease in its degradation, or both. In mdx 
mouse hippocampi, instead, GR protein levels significantly 
decreased in both CORT and vehicle- treated groups compared 
Fig 19.	 Time course of   
genomic and non-genomic 
responses to GCs by mGR and 
cytoplesmic/nuclear GR 
Modified from 213 
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to control (Fig. 20B, B’). This not only strongly suggests a 
deregulation of protein synthesis, as it occurs in chronic 
exposures to GCs, but also reinforces the observation of an 
intrinsic high susceptibility of vehicle-treated mice to stressful 
events. 
 
Fig. 20.	Hippocampal	pGR and GR protein levels 6 h after acute CORT 
treatment. A and B,	representative Western immunoblots of pGR and GR 
protein levels in the hippocampus of wild type and mdx mice, either 
untreated (CTRL) or acutely injected with vehicle (VC) or CORT. A’ and 
B’,	corresponding densitometric analyses. Data are represented as the mean 
± SEM of the optical densities (O.D.) of the bands immunopositive for pGR 
and total GR and analysed by the two tail Student’s t-test. N = 6 
independent experiments. **p ≤ 0.01, ***p ≤ 0.001 vs CTRL; §p ≤ 0.05 vs 
VC. 
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Interestingly, comparing GR basal protein levels between 
control mice of the two genotypes, we 
observed they were significantly 
higher in mdx mice (Fig. 21). No 
differences were, instead observed in 
the level of GR phosphorylation (not 
shown). This suggests that, in 
dystrophic mice, a possible exposure 
to endogenous GCs, because of 
muscle degeneration/inflammation, 
would alter the equilibrium of GC 
synthesis and/or degradation, 
determining its accumulation within 
cells. Since the levels of GR 
phosphorylation are not different 
between the two genotypes, large part 
of this receptor in mdx mice is 
possibly not phosphorylated and, presumably, not functional. 
However, these aspects need a deeper investigation. 
Modulation of hippocampal GR and GILZ mRNA after 6 h 
from acute corticosterone treatment are different between wild 
type and mdx mice 
After evaluating the effect of long-term exposure to an acute 
administration of GCs on the level and activation of the GR, te 
next step was to analyze possible changes in GR transcriptional 
activity. As shown in Fig. 22, GR mRNA levels in both wild 
type and mdx mouse hippocampi did not change neither in 
vehicle nor in CORT treated mice, compared to control. 
Differently, GILZ mRNA significantly increased in both 
vehicle and CORT experimental groups of the wild type 
genotype, but remained unchanged in mdx mouse hippocampi.  
Fig. 21 The box plot 
compare values of the 
mean of optical densities 
(O.D.) of GR the 
immunopositive bands 
in wild type and mdx 
control mice. Data are 
reprensented as the 
mean ± SEM of 6 
independent experiments 
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Fig. 22 Hippocampal GR and GILZ mRNA levels 6h after acute CORT 
treatment. GR and GILZ mRNA levels were evaluated by real time RT-
PCR in the hippocampus of control (CTRL), vehicle (VC) and CORT 
injected wild type and mdx mice. Data are represented as the mean relative 
expression ± SEM. N = 6 independent experiments. **p ≤ 0.01 vs CTRL. 
 
The intersting aspect of this result is that, once again, the 
modulation of this early target of GR activity is enanched in 
wild type mice only, in both injected groups (CORT and 
vehicle). Although these data needs a more accurate evaluation, 
it appears that, despite changes in GR phosphosylation and/or 
protein levels, in mdx mice the genomic response is not 
properly triggered, or at least not as much as it occurs in the 
wild type. This may rely on a defective receptor signaling 
mechanism/s, which in healthy organisms allows its own 
regulation. 
 
Analysis of the levels of proteins involved in the rapid non-
genomic signalling mediated by glucocorticoids 6 h after acute 
corticosterone treatment 
As reported by Groeneweg (78), CORT inhibits the HPA axis 
within minutes and promotes rapid adaptive responses to stress. 
These effects are too rapid to be caused by gene-mediated 
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activity and do not require protein synthesis. Therefore, as 
already investigated for the 90 min group of mice, we 
evaluated the moduation of the non genomic response after 6 h 
from acute CORT treatment. Again, proteins analyzed were 
Cav1, pERK and ERK, with the addition of Cav2. This 
caveolin is primarily associated with the Golgi apparatus, and 
its function is to chaperone proteins, which need to be inserted 
into the plasma membrane, including Cav1 (186). As shown in 
Fig. 23A, A’, 6 h after treatment with either vehicle or GC, 
Cav1 protein levels in the wild type mouse hippocampus 
increased significantly in the CORT experimental group, 
correlating with the increased levels of GR previously 
described. Possibly, large part of the receptor is inserted into 
the membrane as a response to an acute, but prolonged, 
exposure to CORT and Cav1 is needed to stabilize lipid raft-
associated GRs. In addition, similarly to GR, Cav1 levels in the 
mdx mouse hippocampus decreased, compared to control, in 
both vehicle and CORT treated experimental groups, 
supporting the hypothesis of a positive correlation between the 
amount of Cav and stabilized rceptors. However, it needs to be 
clarified that Cav in general are not only expressed by neurons, 
but also at high levels in the endothelial cells of the brain 
vessels and in astrocytes. This means that the changes observed 
in these experimental contexts may also include changes in 
other districts.  
Differently from Cav1, in wild type mice Cav2 protein 
levels did not changes compared to control, after treatments 
(Fig. 23B, B’), but significantly decreased in both vehicle and 
CORT groups of mdx mice. This suggests alterations also in the 
mechanism of Cav1 stabilization into the plasma membrane 
through Cav2, independently from the type of cells.  
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Fig 23. Hippocampal	Cav1, Cav2, ERK and pERK protein levels 6 h 
after acute CORT treatment. A, B, C, D: representative Western 
immunoblots of Cav1, Cav2, pERK and ERK protein levels in the 
hippocampus of wild type and mdx mice either untreated (CTRL), or acutely 
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injected with vehicle (VC) or CORT. A’, B’, C’, D’:	 corresponding 
densitometric analyses. Data are represented as the mean ± SEM of the 
optical densities (O.D.) of the bands immunopositive for each protein and 
analysed by the two tail Student’s t-test. N = 6 independent experiments. *p 
≤	0.05, **p ≤	0.01, ***p ≤	0.01 vs CTRL; §p ≤	0.05 vs VC.  
 
Concerning MAPK, pERK levels in the hippocampus of 
wild type mice tended to decrease following CORT treatment 
compared to controls, although this modulation did not reach 
significance due to a high variability. A significance that was, 
instead, reached in the hippocampus of CORT-injected mdx 
mice (Fig. 23C, C’). Total ERK protein levels, also 
significantly decreased in both genotypes after CORT (wild 
type) or both CORT and vehicle (mdx) treatments (Fig. 23D, 
D’). Therefore, non-genomic signaling 6 h after acute CORT 
treatment shows a general down regulation in mdx mouse 
hippocampi, which was only observed for total ERK in wild 
type mice. 
	
In vivo sub-chronic treatment with dexamethasone 
As already introduced, to date there is not yet a curative 
therapy for DMD, and dystrophic patients are treated with 
chronic administrations of GCs to ameliorate the devastating 
muscular inflammation. Therefore, after evaluating cellular and 
systemic responses of wild type and dystrophic mouse 
hippocampus to acute CORT administration, we performed a 
sub-chronic treatment in vivo by using DEX as exogenous GC. 
This is a powerful synthetic analogue of CORT, largely used in 
the literature for sub-chronic and chronic treatments (187, 188, 
189, 190). Wild type and mdx mice were injected daily with a 
dose of DEX for 9 days. Twenty-four hours after the last DEX 
injection, mice were sacrificed and the hippocampus analysed 
by using biochemical assays to evaluate whether and in which 
direction long-term treatments modulate levels of all proteins 
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so far taken into consideration for the genomic and non-
genomic response to GCs. 
 
GR protein levels are de-regulated in mdx mouse hippocampi 
compared to wild type after sub-chronic dexamethasone 
treatment 
As in the previous studies, pGR and GR protein levels were 
analysed in control wild type and mdx mice and after sub-
chronic administration of either vehicle or DEX. As shown in 
Fig. 24A, A’, pGR protein levels in the wild type mouse 
hippocampus significantly increased after DEX treatment. In 
mdx mice, this increase was revealed also in the vehicle treated 
group, indicating once again the extreme sensibility to stressful 
events of dystrophic mice. Moreover, on the long period, daily 
vehicle treatment induced even a stronger response when 
compared to DEX treatment, suggesting that increasing over a 
certain limit circulating GCs (endogenous plus exogenous) 
down-regulates somehow the amount of receptor ready to be 
phosphorylated.   
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Fig. 24 Hippocampal pGR and GR protein levels after sub-chronic 
DEX treatment. A and B,	representative Western immunoblots of pGR and 
GR protein levels in the hippocampus of wild type and mdx mice, either 
untreated (CTRL) or sub-chronically injected with vehicle (VC) or CORT. 
A’ and B’,	 corresponding densitometric analyses. Data are represented as 
the mean ± SEM of the optical densities (O.D.) of the bands immunopositive 
for pGR and total GR and analysed by the two tail Student’s t-test. N = 8 
independent experiments. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 vs CTRL; §p 
≤ 0.05 vs VC. 
 
At an increase in pGR in wild type mice did not 
correspond an increase in GR protein levels, which remained 
similar to control in both injected experimental groups (24B, 
B’). This is a clear indication that persistent engagement of GR 
does not always positively correlate with the amount of 
receptor. This aspect is even more dramatic in mdx mice, where 
hippocampal GR protein levels significantly decreased in both 
vehicle and DEX-treated mice. As it will be discussed later, 
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chronic exposure to GCs down-regulate GR expression and 
synthesis, an aspect that is deleterious for the hippocampal 
control on the HPA axis (110). These results indicate that in 
dystrophic subjects this cut off line is reached well before wild 
type individuals.  
Modulation of hippocampal GR and GILZ mRNA after sub-
chronic DEX treatment are different between wild type and 
mdx mice 
After evaluating the effect of exposure to a sub-chronic 
administration of GCs on GR protein levels and activation, the 
next step was to analyze possible changes in the GR 
transcriptional activity. As shown in Fig. 25 GR mRNA levels 
in wild type mouse hippocampi did not change neither in 
vehicle nor in CORT treated mice, compared to control. 
	
Fig 25.	 Hippocampal GR and GILZ mRNA levels after sub-chronic 
DEX treatment. GR and GILZ mRNA levels were evaluated by real time 
RT-PCR in the hippocampus of control (CTRL), vehicle (VC) and DEX 
injected wild type and mdx mice. Data are represented as the mean relative 
expression ± SEM. N = 6 independent experiments. *p ≤ 0.05; ***p ≤ 0.001 
vs CTRL. 
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Differently, GR mRNA significantly decreased in both vehicle 
and DEX mdx mouse experimental groups. The interesting 
aspect of this result is that, in the wild type mouse 
hippocampus, GILZ mRNA remained unchanged after both 
DEX and vehicle administration, suggesting a block of this 
early genomic GR response on long lasting exposures to GCs. 
GILZ mRNA in mdx hippocampi, instead, significantly 
decreased after both vehicle and DEX treatment. 
 
Analysis of the levels of proteins involved in the rapid non-
genomic signalling mediated by glucocorticoids after sub-
chronic dexamethasone treatment 
Hippocampal protein levels of Cav1, Cav2, pERK and total 
ERK were analysed after sub-chronic treatment.	 No changes 
were observed for any of the analysed protein between control 
and either vehicle or DEX-injected wild type mice (Fig. 26 A, 
A’; B, B’; C, C’; D, D’), indicating that over a long period this 
form of signalling is not active anymore. This is partly true also 
in mdx mice, with exception of Cav2 and total ERK, which 
significantly increased after both vehicle and DEX treatment, 
compared to control (Fig. 26 B, B’; D, D’), suggesting an over-
production of these proteins, or a down-regulation of their 
degradation, as symptoms of a deregulated response to GR 
persistent engagement.  
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Fig 26: Hippocampal	Cav1, Cav2, ERK and pERK protein levels after 
sub-chronic DEX treatment. A, B, C, D: representative Western 
immunoblots of Cav1, Cav2, pERK and ERK protein levels in the 
hippocampus of wild type and mdx mice either untreated (CTRL), or acutely 
injected with vehicle (VC) or CORT. A’, B’, C’, D’:	 corresponding 
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densitometric analyses. Data are represented as the mean ± SEM of the 
optical densities (O.D.) of the bands immunopositive for each protein and 
analysed by the two tail Student’s t-test. N = 8 independent experiments. *p 
≤	0.05, **p ≤	0.01, vs CTRL. 
 
Quantitative analysis of the neural precursor cell proliferation 
in the hippocampal dentate gyrus 
Lack of Dp427 causes alterations in proliferation and 
differentiation processes due to unusual characteristics in 
neural progenitor cells. In mdx mice, alteration of intracellular 
calcium currents induces alteration in the control of cell cycle 
(191), and the reduced density of pyramidal cells in the CA1 
region of the dorsal hippocampal suggests the presence of 
neurodegenerative and/or anti-neurogenic processes, which 
contribute to the onset of cognitive symptoms (192). 
The general view about neurogenesis is that stress and 
stress hormones inhibit adult neurogenesis by inhibiting neural 
stem cell proliferation. Several studies in the early 1990s 
showed that administration of adrenal hormones in rats 
negatively affect the incorporation of 3H-thymidine, while 
removal of adrenal hormones by adrenalectomy boosters the 
appearance of 3H-thymidine labelled cells (110), suggesting an 
inhibitory role for stress-induced GCs in adult neurogenesis. 
However, the relationship between stress and adult 
neurogenesis seems far more complex than a simple inhibitory 
role. For example, running wheel performance and an enriched 
environment stimulates survival of new born cells and neuronal 
differentiation in mouse brain, while simultaneously increasing 
GC levels (193, 194). In addition, an acute 3 h of 
immobilization stress test, which induces elevation in plasma 
CORT levels, induce cell proliferation in the DG (195). In turn, 
hippocampal neurogenesis may facilitate normalization of GC 
levels after stress (118), suggesting a bi-directional relationship 
between adult hippocampal neurogenesis and regulation of the 
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HPA axis. Clearly, the effect of stress and stress hormones on 
adult neurogenesis is complex. These results can be explained 
by several factors, including the cell types involved, and the 
nature and duration of stress. GR expression in progenitor cells 
and immature neurons (139) also suggests a direct effect of 
circulating GCs on adult neurogenesis. Such a direct role is 
further suggested by the fact that GR activity, mRNA and 
protein levels are tightly regulated by several factors, which 
also regulate adult 
neurogenesis. The 
relationship between GR 
activity and neurogenesis is 
graphically shown in Fig. 27 
(111): low levels of stress in 
mice kept in a poor 
environment, or with a 
sedentary lifestyle, induce 
low levels of proliferation 
and maturation. Controllable 
stress, like enriched 
environments, physical 
activity and learning, coincides with increased levels of GR 
activation and is associated with increased cell proliferation 
and correct integration of mature neurons. Too much GR 
activation, as during uncontrollable stress, negatively affects 
proliferation and neuronal integration.  
Based on these data, we evaluated the effects on NPC 
proliferation in both wild type and mdx mouse DG before and 
after sub-chronic treatment with DEX. The quantitative 
analysis was performed by labelling proliferating cells with 
EdU, injected intraperitoneally in the last three days of the 
DEX treatment.  
Fig. 27 Schematic representation of 
the relationship between GR activity 
and neurogenesis (111). 
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At first, we evaluated and compared the number of EdU+ 
cells in wild type and mdx mouse DG. As shown in Fig. 28, the 
number of proliferating NPS is slightly less in mdx mouse 
hippocampus compared to wild type, although this difference is 
still far from significance (p = 0.13) 
due to the low number of 
experiments so far performed (n = 
3). When comparing the different 
experimental groups within the same 
genotype, we observed that in wild 
type mice the number of EdU+ cells 
didn’t change in the DG of DEX-
treated mice compared to control, 
but significantly decreased compared 
to vehicle injected mice (Fig. 29, as 
also reported by Kim et al. (161). 
Interestingly, following vehicle 
injection we observed a significant 
increase in the number of EdU+ cells, 
suggesting that a mild stress can 
promote cell proliferation, as reported above. Differently, in 
mdx mouse DG, DEX sub-chronic treatment induced a 
significant increase (p ≤ 0.05) in the number of EdU+ cells 
compared to control mice (Fig. 29). These data strongly 
suggest a signalling de-regulation of the cell cycle control in 
mdx mouse NPC, which could interfere with the physiological 
protective mechanism, aiming at reducing cell proliferation in 
adverse conditions.  
Fig. 28: Quantitative 
analysis of EdU+ cell/mean 
DG volume in wild type 
and mdx mice. Data were 
expressed as the mean ± 
SEM and analyzed by the 
two tail Student’s t-test. n = 
3 independent experiments.	
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Fig. 29 Quantitative analysis of NPC proliferation at the DG of wild 
type and mdx mice. Proliferating, EdU+ (green), NPC are counted over the 
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entire DG volume of wild type (WT) and mdx mice of three experimental 
groups: control un-injected (CTRL), vehicle injected (VC) and 
dexamethasone injected (DEX). On the top of the figure, representative 
pictures, with enlarged insets, showing the EdU+ cells distribution along the 
sub-granular zone of the DG. The graphs below report the quantitative 
analysis obtained by counting EdU+ cells along the entire DG in serial cryo-
sections. Numbers are expressed as the mean ± SEM of EdU+ cells/mean 
DG volume and analysed by the Student’s t-test. N = 4 independent 
experiments. *p ≤ 0.05 vs CTRL; §p ≤ 0.05 vs VC. Scale bar: Low and high 
magnifications=100 µM. 
 
Quantitative analysis of apoptotic cells in the hippocampal 
dentate gyrus 
To evaluate whether the differences observed in cell 
proliferation between the two genotypes also corresponded to 
changes in cell death, we performed an immunofluorescence 
quantitative analysis for the presence of the apoptotic marker 
Casp on brain cryo-sections of wild type and mdx mice, before 
and after sub-chronic treatment with DEX. As shown in Fig. 30 
B no changes were observed in the number of apoptotic cells in 
wild type DG after both VC and DEX treatment. Differently, in 
mdx mice, the number of apoptotic cell death tended to 
increase, especially in DEX injected mice. However, this 
increase did not reach significance because due to the low 
number of experiments so far completed. Interestingly, EdU+ 
cells never colocalised with Casp+ cells. 
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Fig. 30 Quantitative analysis of apoptotic cells at the DG of wild type 
and mdx mice A and A’: representative images of Casp3+ and EdU+ cells in 
DG B Apoptotic cells are counted over the entire DG volume of wild type 
(WT) and mdx mice of three experimental groups: control un-injected 
(CTRL), vehicle injected (VC) and dexamethasone injected (DEX). The 
graph report the quantitative analysis obtained by counting Casp+ cells 
along the entire DG in serial cryo-sections. Numbers are expressed as the 
mean ± SEM of Casp+ cells/mean DG volume and analysed by the Student’s 
t-test. N = 4 independent experiments. Scale bar =100 µM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 90	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 91	
Discussion 
Duchenne Muscular Dystrophy (DMD) is a recessive genetic 
disorder associated to the X-chromosome, which determines 
loss of the Dp427 dystrophin protein, and characterized by 
progressive muscular degeneration and non-progressive 
cognitive deficits, which arise during foetal development (192). 
Lack of Dp427 and, at various degree, of its shorter isoforms, 
induces several alterations in both autonomic (51, 52, 54, 55, 
56) and central nervous system (1, 196, 197), including the 
retina (198).	 To date there is no cure for DMD, although 
several innovative therapeutic approaches, aiming at reducing 
the progression of the disease, are applied in clinical protocols 
(199, 59). However, independently of the therapy adopted, the 
standard pharmacological treatment is based on the cyclic 
administration of powerful GC doses, aimed at reducing 
chronic muscular inflammation.	However, a vast literature has 
demonstrated that prolonged use of high doses of GCs induces 
severe side effects, also affecting the nervous system. 
Specifically, in prolonged stressful events, high and persistent 
levels of CORT have been proposed to be the mediators of 
detrimental effects, such as memory and cognition impairment, 
major depression, anxiety disorders, and post-traumatic stress 
disorder, reduced structural and functional plasticity (61, 200, 
135). In physiological conditions, GCs are secreted by the 
adrenal gland in response to signals from the HPA axis, and 
represent the hormones by which the body responds to stressful 
events. Among the brain areas involved in stress response is the 
hippocampus, the activation of which by GCs, is necessary to 
de-regulate the HPA axis activity and reduce GC release (176, 
201).	In DMD patients, as in mdx mice, the hippocampus is one 
of the brain areas mostly affected by the lack of Dp427.  
Therefore, the experimental work presented in theses has 
been aimed at understanding whether hippocampal responses to 
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either acute of sub-chronic GC administration was different 
between wild type and dystrophic mice. The parameters so far 
chosen to unveil this response were: expression, synthesis and 
localization of the GR, modulation of the GR signalling (both 
genomic and non-genomic), impact on proliferation of the NPC 
localized at the DG sub-granular zone, a process reported to be 
compromised under stress conditions. 
 
The response of cultured hippocampal neurons to acute 
corticosterone administration is different between wild type 
and mdx mice 
Working with an in vitro system has the advantage to analyse a 
physiological/pathological response isolated from the in vivo 
contest, rich in background. The first part of this doctoral 
study, has been cantered to uncover how isolated hippocampal 
neurons respond to acute (60 min) administration of different 
CORT concentration: 1 μM and 10 μM.  
A first interesting data is that E18 mdx mouse 
hippocampi, the embryonic stage at which hippocampal neuron 
culture were established, had significantly lower levels of GR 
compared to wild type, while the level of phosphorylation was 
comparable. This aspect already indicates that mdx mouse 
hippocampi suffer some long-lasting exposure to endogenous 
GCs, possibly derived from maternal blood stream as 
demonstrated by plasma corticosterone measurement. In fact, 
dystrophic female also experience recurrent muscular 
degenerations, which in turn increase the levels of endogenous 
anti-inflammatory molecules, as CORT. Therefore, this down-
regulation of GR levels is consistent with the literature, 
according which increased exposure of placenta to GC, from 
either maternal or foetal circulation, alters the expression of 
11β-HSD2 and of a number of genes involved in its endocrine 
function. In the foetus, GC overexposure affects almost all the 
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endocrine systems, which are active during late gestation, 
including the HPA axis itself (169, 202). If considering that the 
levels of phosphorylated receptor is similar to that in the wild 
type mice, we could also speculate that in mdx mice a larger 
proportion, compared to wild type, is active. This aspect may 
possibly comply with the large body of literature describing the 
deleterious genetic and epigenetic pre-natal stress effects over 
foetuses (203, 204). 
That the GR response is already “compromised” in mdx 
mouse hippocampal neurons could be also evinced from the 
different response that hippocampal neurons of the two 
genotypes have following acute administration of exogenous 
CORT. While wild type mouse neurons respond as expected, 
i.e. by increasing receptor phosphorylation, protein level and 
gene expression compared to control conditions (incubation 
with vehicle), GR in mdx mouse neurons do not undergo to 
further phosphorylation, their protein levels significantly 
decrease compared to control conditions and mRNA levels are 
only slightly up-regulated. Biochemical and molecular biology 
data were further validated by immunocytochemistry. This 
response strongly suggests that hippocampal neuron of 
dystrophic mice respond in a way more similar to an in vivo 
chronic exposure to GCs, in which the hippocampus inhibitory 
activity over the HPA axis is dramatically reduced or abolished 
(105, 135). A further important aspect that came out from this 
experiments is that CORT per se induces a dose-dependent 
degree of neuronal death by apoptosis, evaluated by 
quantitative Casp 3 immunocytochemistry,  
 
In vivo, wild type and mdx mouse hippocampal neurons 
respond differently to acute corticosterone treatment  
A different response between wild type and mdx mice was also 
obtained following acute CORT administration protocol in 
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vivo. In this case, two groups of mice of both genotypes were 
injected only once with a dose of either CORT or vehicle and 
then scarified after 90 min (short-term response) or 6 h (long-
term response). The results were compared to their respective 
un-injected control mice. Expression of hippocampal GR and 
its activation are key factors in the correct coordination of 
stress responses, as they determine the sensitivity of this 
cerebral region to GC and, hence, the direction of its 
modulation of the HPA axis activity (176, 201). Again, quite 
similar to what observed in the in vitro experiments, 90 min 
after CORT exposure, both wild type and mdx mice respond by 
significantly increasing levels pGR compared to control, 
indicating the CORT has reached the hippocampus and 
recognized its receptors. However, a slight increase was also 
observed in the vehicle-injected mdx mouse group, suggesting 
a peculiar susceptibility of dystrophic mice to stressful 
conditions (see later in this discussion). Differences between 
the two genotypes were observed in the total GR protein levels: 
in the wild type mouse hippocampus their remaine unchanged, 
as expected since time for new protein synthesis is presumably 
still too short; differently, those in mdx mice decrease 
significantly in both vehicle and CORT groups. This opens two 
questions: first, such a specific reduction in protein levels 
suggests an increase in their degradation and/or a decrease in 
their normal synthesis. The way for this to occur is that 
hippocampal neurons perceive this treatment as a further load 
of GC, which triggers a response typical of “chronic” exposure 
to stressors (205). This would be in accord to what previously 
described in the in vitro experiments. The second important 
question is that mice in the vehicle group respond similarly to 
those who received CORT, opening the interesting question on 
whether mdx mice had a hypersensitivity to experimental 
treatments, independently from injection of exogenous GCs. 
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This would mean that mouse manipulation by the experimenter 
and injections are per se capable of inducing a powerful stress 
response, probably triggered by release of noradrenaline from 
the autonomic nervous system, activation of amygdala and 
release of endogenous GCs from the adrenal gland. This 
hypothesis is consistent with data from a study conducted by 
Vaillend and Choussenot (178), showing a significant higher 
response of mdx mice, compared to wild type, to different 
stress-behavioural tests, with high levels of freezing in 
response to even the simple experimenter grip. This could be 
related to the fact that the basal CORT levels in wild type and 
mdx mice are different. In addition, coming back to our data, 
GR protein levels observed in the two injected groups were 
similar, suggesting that additional CORT does not further 
increase a systemic response, which could be considered 
“saturated”. It is important to remember that both amygdala 
and the sympathetic nervous system actively participate in the 
stress response, and that shortly after stress onset, 
noradrenaline levels in the baso-lateral amygdala (BLA) are 
transiently elevated. Corticosteroids reach the same area 
somewhat later and remain elevated for approximately 1–2 h. 
Therefore, for a restricted period of time, BLA neurons are 
exposed to high levels of both hormones. Later on, 
corticosteroids normalize BLA activity (delayed effect via GR), 
a phase in which higher cognitive controls seem to be restored 
(206).  
Supporting this hypothesis are the results obtained by 
gene expression analysis: GR expression does not change in 
wild type mouse hippocampus, coherent with the unchanged 
levels of GR. Differently, the significant decrease in the CORT 
group of mdx mice suggests an overloading of stressful 
response, enough to activate a genomic response, that in the 
case of heavy and prolonged exposures to GCs has been 
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demonstrated to decrease GR expression (205). An interesting 
aspect, deserving a deeper analysis, is the significant increase 
in GILZ gene expression in both vehicle and CORT groups in 
wild type mice. GILZ is a transcription factor, the expression of 
which is early regulated by GR activity and that, in turn, 
modulates the expression of other downstream genes (207, 
209). No changes in GILZ mRNA levels were observed in mdx 
mouse hippocampi.  
Coherent with all these considerations are the data 
reporting higher GR protein levels in control mdx mouse 
hippocampus compared to wild type.  This means that 
somehow adult mice are continuously, or recurrently, 
stimulated; therefore, in the presence of humoral and/or 
hormonal “overload” a negative feedback mechanism would be 
triggered. 
The results obtained by the immunohystochemical 
investigation of GR and pGR distribution in the hippocampus, 
before and after CORT administration, were in accord to what 
described by biochemistry. In addition, GR localization was 
predominantly in the DG and CA1 regions of the hippocampus, 
areas implicated in neurogenesis and cognitive function, 
respectively (208). GR phosphorylation was, instead, more 
evident in CA1 sub-regions, although a faint and more 
widespread immunolabelling could be appreciated at higher 
magnification. Obviously, the amount of pGR is relatively 
lower compared to the total GR and its signal could be below 
the resolution power of the techniques.  
Analysis of some of the parameters of the non-genomic 
response again highlighted some important differences between 
the two genotypes. ERK is one of the early downstream 
proteins in both membrane-bound and cytoplasmic GR 
signalling, and its activation represents a link between the 
classical genomic and the rapid non-genomic pathways (209). 
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Ninety minutes after CORT injection of wild type mice, 
phosphorylation (activation) of ERK in the hippocampus was 
significantly higher compared to control and vehicle groups, 
while it did not change in mdx mice, suggesting some 
impediment in the correct transmission of the fast signalling.  
Supporting this hypothesis is the lack of changes in protein 
levels of Cav1, a protein stabilized by the Dp427-DGC, as 
demonstrated for Cav3 in skeletal muscles (210) and one of the 
lipid raft proteins thought to be involved in mGR stabilization. 
The GR-mediated Cav1 activation, which involves its 
phosphorylation (180), participates in the MAPK-driven 
intracellular signalling pathway. Therefore, this apparent 
insensitivity to treatments in dystrophic mice could suggest a 
further destabilization of Cav1 into the membrane and a non-
appropriate downstream signalling to ERK.  
As expected, six hours after CORT treatment, no more 
changes in pGR were observed, in neither one of the genotypes. 
Total GR levels, instead, were significantly increased in the 
wild type mouse hippocampus after CORT administration, as a 
consequence of early GR activation. Differently, in both 
vehicle and CORT injected mdx mice, GR levels decreased 
significantly, exactly as observed after 90 min, again arguing in 
favour of a stressor-saturated system.  
The analysis of the non-genomic signalling parameters 
again identified important differences between the two 
genotypes.  After a longer time from CORT administration, 
protein levels of Cav1 increased in the wild type mouse 
hippocampus, suggesting readjustment of newly synthesized 
receptors into the plasma membrane. The ERK system, instead, 
was down regulated. A similar silencing was also observed in 
both vehicle and CORT treated mdx mouse hippocampi. 
However, a powerful decrease was also observed in the levels 
of Cav1 and Cav2, a protein mainly located within the Golgi 
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apparatus membrane, working as chaperone in the transport of 
membrane proteins, including Cav1 (97). One hypothesis we 
can pursue is that, in mdx mice, Cav1 activity and, hence, 
protein levels would be decreased by a diminished stabilization 
into the plasma membrane caused by lack of Dp427 in the 
DGC. However, a more general consideration is that the 
caveolins we observe in tissues extract include not only those 
localized in neurons, but also those expressed by endothelial 
cells and astrocytes. Therefore, what we observe is possibly a 
mean of the total levels of Cav within different cell types. 
Nevertheless, it deserves to be noticed that in mdx mice both 
treatment with vehicle and CORT significantly reduce protein 
levels of GR, Cav1 and Cav2, suggesting a close connection in 
the physiology of these proteins.  
 
In vivo, wild type and mdx mouse hippocampal neurons 
respond differently to dexamethasone sub-chronic treatment  
The following experimental set of experiments aimed at 
uncovering the hippocampal response to prolonged GC 
treatments, a procedure closer to the therapeutic treatments 
adopted in DMD. For this procedure, it was used DEX, a 
powerful analogue of CORT, widely used for long-term 
studies.   
Prolonged DEX treatments kept levels of pGR in the 
hippocampus of wild type mice significantly higher than those 
in the control, suggesting that receptor activation adjusted to 
increased levels of GCs. Differently, levels of total GR and of 
all proteins analysed for the non-genomic signalling were 
comparable between the three experimental groups, suggesting 
that constant (one injection/day for 9 days) GR signalling over 
a prolonged period of time could adjust the “executive” system 
(GR and proteins of the non-genomic signalling) at 
basal/physiological levels. Differently, in mdx mouse 
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hippocampi, pGR levels increased significantly in both vehicle 
and DEX groups, reiterating the hypothesis of an over-
sensibility of mdx mice to manipulation. The higher degree of 
GR phosphorylation in the vehicle group compared to DEX, 
may indicate again that the system begins to respond as it was 
under chronic and repeated stressful waves. As a matter of fact, 
GR protein levels were significantly decreased in both injected 
groups compared to control. GR and GILZ gene expression 
decrease after 9 days of vehicle and DEX administration only 
in mdx mice. Data from the literature have demonstrated that a 
chronic psychosocial stress, or the administration of high DEX 
concentrations, induce a reduction in both GR protein and its 
mRNA levels; however, in wild type condition we observed 
only a slight tendency to decrease, but this reduction does not 
reached significance, probably because our sub-chronic 
treatment represents a time that is still too short to appreciate 
important changes in gene expression (which are instead 
observed in chronic treatments). Unlike, an acute stress, or 
CORT administration, would induce an increase in receptor 
levels (211). 
Dystrophic mice also show differences compared to wild 
type in the levels of some proteins of the non-genomic 
signalling. Specifically, while no differences among the three 
experimental groups were observed in the protein levels of 
Cav1 and pERK (similar to wild type), those of Cav2 and total 
ERK increased significantly in both DEX and vehicle groups. 
This could be a long-term response to protein level adjustments 
(decreased degradation) in a system that is destabilized 
compared to the wild type. 
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Proliferation of neural precursor cells in wild type and mdx 
mouse hippocampus is differently affected by dexamethasone 
sub-chronic treatment  
Hippocampal NPCs proliferation is a mechanism negatively 
influenced by stress (201), i.e. chronic GR activation induce an 
inhibition in NPC proliferation and following adult 
neurogenesis (161). To analyse how stem cell proliferation in 
the sub-granular zone of the hippocampal DG is altered in our 
experimental model, we labelled proliferating cells by EdU and 
performed a quantitative analysis in control, vehicle-injected 
and DEX-injected wild type and mdx mice. The results reported 
in this thesis showed significant decrease in NPC proliferation 
after DEX sub-chronic treatment of wild type mice compared 
to vehicle. This result is in agreement with other studies on 
different animal models (161). Interestingly, NPC proliferation 
after DEX administration did not change compared to control, 
suggesting inhibition of cell proliferation in stress condition, 
while it significantly increased after VC treatment. This data 
suggests that the experimental manipulation itself represents a 
mild stress for wild type mice that promotes NPC proliferation 
(111). Differently, in mdx mouse hippocampus there was a 
significant increase in NPC proliferation, compared to the other 
two groups. Indications are that GC signalling by proliferating 
hippocampal cells is differently perceived by cells of the two 
genotypes. The relationship between stress and NPCs 
proliferation is mediated by GR activation, which in these cells 
positively and negatively regulates the transcription of 
important genes for cell cycle control and differentiation (111). 
However, the modulation by stress of NPCs proliferation is 
complex and depends on both degree of GR activation and 
levels of circulating GCs. In fact, a “controllable” stress, like 
physical activity, is associated with an increase in NPC 
proliferation, on the contrary, a chronic “uncontrollable” stress, 
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results in a strong reduction; the discriminating factor between 
the two events seems to be the degree of GR activation (111). 
In this work, mdx mouse sub-chronic DEX treatment increased 
GR phosphorylation levels, while reducing hippocampal GR 
protein levels, suggesting that such a negative regulation could 
affect other cellular events controlled by GR signalling. The 
important aspect of these results, however, is that, under stress 
conditions, healthy wild type mice trigger a typical temporary 
homeostatic response, which we suppose to be protective of 
such a delicate mechanism. Differently, in dystrophic mice 
somehow the steps regulating the incidence of GC on cell 
cycles are corrupted, actually un-inhibiting a possible ongoing 
control over cell proliferation in un-injected animals.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 102	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 103	
Conclusions 
The data presented in this thesis indicate that mdx mice, one of 
the most used animal models of DMD, respond differently to 
stressful events, such as acute or sub-chronic GC 
administration.	 Possibly,	 these differences may stem from a 
“pre-sensitized” condition, considering that dystrophic subjects 
are afflicted by continuous cycles of skeletal muscle 
degeneration, which increase levels of circulating CORT. In 
addition, reports describe mdx mice quite susceptible to 
different form of stress, as also evidenced by the response to 
vehicle treatments in this study. What could be, therefore, the 
link between a dystrophic status and the peculiar response to 
elevated concentrations of GC? One before all is that the 
hippocampus (in both DMD patients and mdx mice) shows 
different degrees of structural and functional alterations 
induced by the lack of Dp427.  These physiological alterations 
could be per se a ground of different cell behaviour to stress 
hormones. Second, Dp427 and the DGC are implicated in the 
stabilization of cortical cytoskeletal and membrane proteins, 
among which caveolins. These are also localized into lipid 
rafts, membrane regions associated to mGR, suggesting that a 
partial convergence between the two systems may exist. 
Another aspect is the secondary effect that absence of Dp427 
has on the expression of other genes, as demonstrated by us in 
previous studies. This would further complicate the possible 
scenario in which stress-related events develop.  
It is now proven that DMD is not just a muscle disorder 
characterized by severe damage of striated muscles, but it is 
associated with various cognitive disabilities. Although 
neurological defects are reported in both DMD patients and 
animal models, they are not considered relevant in the 
symptomatic picture of DMD, mainly because of premature 
patient death. To date, therapeutic treatments in clinical trial 
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potentially increase DMD patient life of about ten years.	In this 
perspective, the onset of neurological symptoms will 
paradoxically worsen the quality of life. Moreover, very few 
studies have assessed the mental health of children and 
adolescent with DMD, although they are at great risk of 
developing depression and anxiety disorders. Indeed, the 
conditions of life of a child affected by DMD are very difficult 
compared to their peers. Soon they lose the ability to walk and 
are forced to live in a wheelchair. These discomforts, which 
certainly generate stress, are added to the alterations of specific 
brain regions, among which hippocampus, which are linked to 
the lack of Dp427 (and in DMD patients also of other 
isoforms). To this situation, already complex in itself, are 
added the chronic and massive treatments with GCs, which 
worsen the neurological condition of patients and compromise 
the correct hippocampus function and the systems associated 
with it (i.e. HPA axis). This generates defects in all those 
districts and signaling systems that allow our body to respond 
to stressful events and to restore homeostasis by regulating the 
levels of circulating GCs. 
Importantly, published data to date have not indicated 
GC-like adverse effects associated with GILZ, suggesting that 
GILZ exerts immunosuppressive effects that mimic those of 
GCs but occur via distinct pathways.	 The similarities and 
divergence between the effects of GILZ and GC suggest the 
potential use of GILZ-based therapies in improving GC 
efficacy while reducing GC metabolic toxicity, and thus the 
development of new treatment strategies to replace supplement 
or even replace GC. (212) Further investigation is required to 
determine whether GILZ induces GC-related adverse metabolic 
effects. If confirmed, this will support the hypothesis that GILZ 
therapeutic effects mimic those of GCs but lack GC-like 
metabolic effects. As a result, GILZ-based gene therapy has 
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great potential in the therapy of human inflammatory diseases. 
In the hope that new therapies could extend the life span 
of the young DMD patients by reducing and slowing down the 
muscular degeneration, it is even more important to go deeper 
in the comprehension of how hippocampal neurons, already 
affected since embryonic development by DMD, respond to 
chronic or sub-chronic administrations of GCs. 
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